CUMULATIVE
SUPPLEMENT 5
MAY 2003

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2003


HYMAN, PHELPS
&MCNAMARA, P.C.
WASHINGTON, DC
DEMCO

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23RD EDITION

Cumulative Supplement 5

May 2003

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 5
May 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BAYER CORP (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
BAYER CORP CONSUMER CARE DIV (BAYER CORP CONSUMER)	BAYER CORP CONSUMER CARE LLC (BAYER)
BAYER CORP PHARMACEUTICALS DIV (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
SIDMAK LABORATORIES INC (SIDMAK LABS)	PLIVA INC (PLIVA)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

PRODUCT NAME	APPLICANT	TE CODE	STRENGTH	NDA	PRODUCT
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001
NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is $108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm

The Internet version of the monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder.orange/23bookpub.pdf

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.
The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:

http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.htm

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2002	JUN 2003	SEP 2003	DEC 2003
DRUG PRODUCTS LISTED	10465			
SINGLE SOURCE	2420 (23.1%)			
MULTISOURCE	7939 (75.9%)			
THERAPEUTICALLY EQUIVALENT	7659 (73.2%)			
NOT THERAPEUTICALLY EQUIVALENT	280 (2.7%)			
EXCEPTIONS	106 (1.0%)			
NEW MOLECULAR ENTITIES APPROVED	6			
NUMBER OF APPLICANTS	598			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL

ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE

+		MIKART	325MG/15ML;50MG/15ML;40MG/15ML	N40387 001	JAN 31, 2003	JAN	NEWA

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

>A>	AB		AXIOM PHARM	325MG;50MG;40MG	N89536 001	FEB 16, 1988	MAY	CAHN
>D>	AB		HALSEY	325MG;50MG;40MG	N89536 001	FEB 16, 1988	MAY	CAHN

FIORICET

	AB	+	WATSON PHARMS	325MG;50MG;40MG	N88616 001	NOV 09, 1984	APR	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

	AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPAHTE

	AA		ANDRX PHARMS	300MG;15MG	N40443 001	JAN 22, 2003	JAN	NEWA
	AA			300MG;30MG	N40443 002	JAN 22, 2003	JAN	NEWA
	AA			300MG;60MG	N40443 003	JAN 22, 2003	JAN	NEWA

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		RANBAXY	300MG;60MG	N87083 001		JAN	CAHN

ACETAMINOPHEN W/ CODEINE PHOSPHATE #3

	AA		RANBAXY	300MG;30MG	N85868 001		JAN	CAHN

CODRIX

+			ANDRX PHARMS	500MG;30MG	N40441 001	MAR 27, 2003	MAR	NEWA
+				500MG;15MG	N40447 001	FEB 26, 2003	FEB	NEWA
+				500MG;60MG	N40488 001	MAR 28, 2003	MAR	NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

	AA		ABLE	650MG;7.5MG	N40474 001	JAN 02, 2003	JAN	NEWA

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA		ABLE	500MG;7.5MG	N40490 001	MAY 21, 2003	MAY	NEWA
>A>	AA		ANDRX PHARMS	500MG;5MG	N40493 001	MAY 28, 2003	MAY	NEWA
>A>	AA			660MG;10MG	N40495 001	MAY 28, 2003	MAY	NEWA
>A>	AA			750MG;7.5MG	N40494 001	MAY 28, 2003	MAY	NEWA
>A>	AA		AXIOM PHARM	500MG;5MG	N40236 001	SEP 25, 1997	MAY	CAHN
>A>	AA			650MG;10MG	N40240 001	NOV 26, 1997	MAY	CAHN
>A>	AA			650MG;7.5MG	N40240 002	NOV 26, 1997	MAY	CAHN
>A>	AA			750MG;7.5MG	N40236 002	SEP 25, 1997	MAY	CAHN
>D>	AA		HALSEY	500MG;5MG	N40236 001	SEP 25, 1997	MAY	CAHN
>D>	AA			650MG;10MG	N40240 001	NOV 26, 1997	MAY	CAHN
>D>	AA			650MG;7.5MG	N40240 002	NOV 26, 1997	MAY	CAHN
>D>	AA			750MG;7.5MG	N40236 002	SEP 25, 1997	MAY	CAHN
	AA		MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003	JAN	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

>A>	AA	AXIOM PHARM	500MG;5MG	N40219	001	JAN 22, 1998	MAY	CAHN
>D>	AA	HALSEY	500MG;5MG	N40219	001	JAN 22, 1998	MAY	CAHN

ACYCLOVIR
CAPSULE; ORAL
ACYCLOVIR

	AB	AAIPHARMA	200MG	N74833	001	APR 22, 1997	APR	CAHN

ALBUTEROL SULFATE
SOLUTION; INHALATION
ALBUTEROL SULFATE

	AN	NOVEX	EQ 0.5% BASE	N76391	001	APR 01, 2003	APR	NEWA

ALFENTANIL HYDROCHLORIDE
INJECTABLE; INJECTION
ALFENTA

	AP +	AKORN	EQ 0.5MG BASE/ML	N19353	001	DEC 29, 1986	MAR	CAHN

ALMOTRIPTAN MALATE
TABLET; ORAL
AXERT

		JANSSEN ORTHO	EQ 6.25MG BASE	N21001	001	MAY 07, 2001	APR	CAHN
	+		EQ 12.5MG BASE	N21001	002	MAY 07, 2001	APR	CAHN

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
INJECTABLE; INJECTION
CERNEVIT-12

		@ BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60UGM/VIAL;200 IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG /VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14 MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL	N20924	001	APR 06, 1999	MAR	DISC

ALPRAZOLAM
TABLET, EXTENDED RELEASE; ORAL
XANAX XR

		PHARMACIA AND UPJOHN	0.5MG	N21434	001	JAN 17, 2003	JAN	NEWA
			1MG	N21434	002	JAN 17, 2003	JAN	NEWA
			2MG	N21434	003	JAN 17, 2003	JAN	NEWA
	+		3MG	N21434	004	JAN 17, 2003	JAN	NEWA

AMANTADINE HYDROCHLORIDE
CAPSULE; ORAL
AMANTADINE HCL

	AB	GENEVA PHARMS	100MG	N71293	001	FEB 18, 1987	APR	CAHN

AMCINONIDE
CREAM; TOPICAL
AMCINONIDE

>A>	AB		ALTANA	0.1%	N76065 001	MAY 15, 2003	MAY	NEWA
>D>	AT		TARO PHARM INDS	0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
>A>	AB			0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
	AT			0.1%	N76229 001	MAY 31, 2002	APR	NEWA

CYCLOCORT

>D>	AT	+	FUJISAWA HLTHCARE	0.1%	N18116 002		MAY	CTEC
>A>	AB	+		0.1%	N18116 002		MAY	CTEC
	AT	+		0.1%	N18116 002		APR	CFTG

OINTMENT; TOPICAL
AMCINONIDE

	AB		TARO PHARM INDS	0.1%	N76367 001	MAR 19, 2003	MAR	NEWA

AMIODARONE HYDROCHLORIDE
INJECTABLE; INJECTION
AMIODARONE HCL

	AP		APOTEX	50MG/ML	N76394 001	APR 25, 2003	APR	NEWA

CORDARONE

	AP	+	WYETH PHARMS INC	50MG/ML	N20377 001	AUG 03, 1995	MAR	CAHN

TABLET; ORAL

	AB		WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985	MAR	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
TABLET; ORAL
ETRAFON 2-10

			@ SCHERING	10MG;2MG	N14713 007		MAR	DISC

ETRAFON 2-25

			@ SCHERING	25MG;2MG	N14713 004		MAR	DISC

ETRAFON-FORTE

			@ SCHERING	25MG;4MG	N14713 006		MAR	DISC

AMMONIUM LACTATE
CREAM; TOPICAL
AMMONIUM LACTATE

	AB		TARO	EQ 12% BASE	N75883 001	APR 10, 2003	APR	NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

>A>	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL							
>A>	PREVPAC							
>A>		+	TAP PHARM	500MG;500MG;30MG	N50757 001	DEC 02, 1997	MAY	CDFR
>D>	CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL							
>D>	PREVPAC							
>D>		+	TAP PHARM	500MG;500MG;30MG	N50757 001	DEC 02, 1997	MAY	CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM
FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB		RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	N65132 001	MAR 19, 2003	MAR	NEWA
	AB			400MG/5ML;EQ 57MG BASE/5ML	N65132 002	MAR 19, 2003	MAR	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE								
CAPSULE, EXTENDED RELEASE; ORAL								
ADDERALL XR 10								
		SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	JAN	CAHN
ADDERALL XR 15								
		SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JAN	CAHN
ADDERALL XR 20								
		SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	JAN	CAHN
ADDERALL XR 25								
		SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JAN	CAHN
ADDERALL XR 30								
	+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	JAN	CAHN
ADDERALL XR 5								
		SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JAN	CAHN
TABLET; ORAL								
ADDERALL 12.5								
AB		SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR	CFTG
ADDERALL 15								
AB		SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR	CFTG
ADDERALL 7.5								
AB		SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR	CFTG
DEXTROAMP SACCHARATE, AMP ASPARATE, DEXTROAMP SULFATE AND AMP SULFATE								
>A> AB		WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY	NEWA
>A> AB			2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY	NEWA
>A> AB			5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY	NEWA
>A> AB			7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY	NEWA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE								
AB		BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA
AB			3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA
AMPRENAVIR								
CAPSULE; ORAL								
AGENERASE								
		GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
	+		150MG	N21007 002	APR 15, 1999	MAR	CMFD
SOLUTION; ORAL								
	+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD
APREPITANT								
CAPSULE; ORAL								
EMEND								
		MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
	+		125MG	N21549 002	MAR 26, 2003	MAR	NEWA
ASPIRIN; BUTALBITAL; CAFFEINE								
CAPSULE; ORAL								
FIORINAL								
AB	+	WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986	MAR	CAHN
TABLET; ORAL								
AB	+	WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986	MAR	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE NO 3

AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990	MAR	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>A>	AA	AXIOM PHARM	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998	MAY	CAHN
>D>	AA	HALSEY	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998	MAY	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

>D>	LILLY	5MG	N21411 001	NOV 26, 2002	MAY	DISC
>A>	@	5MG	N21411 001	NOV 26, 2002	MAY	DISC

AZATHIOPRINE

TABLET; ORAL

AZASAN

	AAIPHARMA LLC	25MG	N75252 002	FEB 03, 2003	FEB	NEWA
		50MG	N75252 001	JUN 07, 1999	FEB	NEWA
AB		75MG	N75252 003	FEB 03, 2003	FEB	NEWA
		100MG	N75252 004	FEB 03, 2003	FEB	NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+	MEDPOINTE	0.05%	N21127 001	MAY 22, 2000	APR	CAHN

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

@	GLAXOSMITHKLINE	0.042MG/INH	N18153 001		MAR DISC

AEROSOL, METERED; NASAL

BECONASE

@	GLAXOSMITHKLINE	0.042MG/INH	N18584 001		MAR DISC

VANCENASE

@	SCHERING	0.042MG/INH	N18521 001		MAR DISC

BETAMETHASONE

TABLET; ORAL

CELESTONE

@	SCHERING	0.6MG	N12657 003		FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

>D>	AB	SAVAGE LABS	EQ 0.05% BASE	N19138 001	JUN 26, 1984	MAY	CRLD
>A>	AB +		EQ 0.05% BASE	N19138 001	JUN 26, 1984	MAY	CRLD
>D>		DIPROSONE					
>D>	AB +	SCHERING	EQ 0.05% BASE	N17536 001		MAY	DISC

>A>		@		EQ 0.05% BASE				
		GEL, AUGMENTED; TOPICAL			N17536 001			DISC
>A>		BETAMETHASONE DIPROPIONATE						
>A>	AB	ALTANA		EQ 0.05% BASE				
		DIPROLENE			N75276 001	MAY 13, 2003	MAY	NEWA
>D>		+ SCHERING		EQ 0.05% BASE				
>A>	AB +			EQ 0.05% BASE	N19408 002	NOV 22, 1991	MAY	CFTG
					N19408 002	NOV 22, 1991	MAY	CFTG
		BISOPROLOL FUMARATE						
		TABLET; ORAL						
		ZEBETA						
	AB	WYETH PHARMS INC		5MG				
	AB +			10MG	N19982 002	JUL 31, 1992	MAR	CAHN
					N19982 001	JUL 31, 1992	MAR	CAHN
		BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE						
		TABLET; ORAL						
		ZIAC						
	AB	WYETH PHARMS INC		2.5MG;6.25MG				
	AB			5MG;6.25MG	N20186 003	MAR 26, 1993	MAR	CAHN
	AB +			10MG;6.25MG	N20186 001	MAR 26, 1993	MAR	CAHN
					N20186 002	MAR 26, 1993	MAR	CAHN
>A>		BORTEZOMIB						
>A>		INJECTABLE; INTRAVENOUS						
>A>		VELCADE						
>A>		+ MILLENNIUM PHARMS		3.5MG/VIAL	N21602 001	MAY 13, 2003	MAY	NEWA
		BRIMONIDINE TARTRATE						
		SOLUTION/DROPS; OPHTHALMIC						
>A>		BRIMONIDINE TARTRATE						
>A>		+ BAUSCH AND LOMB		0.2%	N76260 001	MAY 28, 2003	MAY	NEWA
		BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE						
		SYRUP; ORAL						
		DIMETANE-DX						
		@ ROBINS AH		2MG/5ML;10MG/5ML;30MG/5ML	N19279 001	AUG 24, 1984	MAR	DISC
		MYPHETANE DX						
	AA +	MORTON GROVE		2MG/5ML;10MG/5ML;30MG/5ML	N88811 001	JUN 07, 1985	MAR	CTEC
>A>		BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE						
>A>		INJECTABLE; INJECTION						
>A>		DUOCAINE						
>A>		+ AMPAHSTAR		0.375% (37.5MG/10ML);1% (100MG/10ML)	N21496 001	MAY 23, 2003	MAY	NEWA
		BUSPIRONE HYDROCHLORIDE						
		TABLET; ORAL						
		BUSPIRONE HCL						
	AB	EGIS		15MG	N75119 003	JAN 23, 2003	JAN	NEWA
		CALCITRIOL						
		INJECTABLE; INJECTION						
		CALCITRIOL						
	AP	AAIPHARMA		0.001MG/ML	N75766 001	FEB 20, 2003	FEB	NEWA

AP		0.002MG/ML	N75766 002	FEB 20, 2003	FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003	MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003	MAR	NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

>D>	+ ORPHAN MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N20577 001	SEP 27, 1996	MAY	CAHN
>A>	+ QOL MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N20577 001	SEP 27, 1996	MAY	CAHN

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

	+ MIKART	4MG/5ML	N40458 001	APR 25, 2003	APR	NEWA

TABLET; ORAL

	+ MIKART	4MG	N40442 001	MAR 19, 2003	MAR	NEWA

CARVEDILOL

TABLET; ORAL

COREG

	+ GLAXOSMITHKLINE	12.5MG	N20297 002	SEP 14, 1995	APR	CRLD
		25MG	N20297 001	SEP 14, 1995	APR	CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	RANBAXY	EQ 125MG BASE/5ML	N65115 001	MAR 26, 2003	MAR	NEWA
AB		EQ 250MG BASE/5ML	N65115 002	MAR 26, 2003	MAR	NEWA
AB		EQ 500MG BASE/5ML	N65115 003	MAR 26, 2003	MAR	NEWA

DURICEF

AB	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		MAR	CFTG
AB		EQ 250MG BASE/5ML	N50527 003		MAR	CFTG
AB	+	EQ 500MG BASE/5ML	N50527 001		MAR	CFTG

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

>A>	+ PURDUE PHARMA LP	200MG	N21222 001	AUG 29, 2001	MAY	CAHN
>D>	+ TAP PHARM	200MG	N21222 001	AUG 29, 2001	MAY	CAHN

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

	@ LEDERLE	100MG/5ML	N50622 001	APR 28, 1989	APR	DISC

TABLET; ORAL

	@ LEDERLE	200MG	N50621 001	APR 28, 1989	APR	DISC
	@	400MG	N50621 002	APR 28, 1989	APR	DISC

CEFOXITIN SODIUM
INJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER
\+ MERCK
\+ EQ 20MG BASE/ML — N63182 001 JAN 25, 1993 MAR CRLD
\+ EQ 40MG BASE/ML — N63182 002 JAN 25, 1993 MAR CRLD

CEFUROXIME AXETIL
TABLET; ORAL
CEFUROXIME AXETIL
AB RANBAXY
AB EQ 125MG BASE — N65118 001 APR 25, 2003 APR NEWA
AB EQ 250MG BASE — N65118 002 APR 25, 2003 APR NEWA
AB EQ 500MG BASE — N65118 003 APR 25, 2003 APR NEWA

CEPHALOTHIN SODIUM
INJECTABLE; INJECTION
CEPHALOTHIN SODIUM
\+ BRISTOL
\+ EQ 1GM BASE/VIAL — N62464 001 MAY 07, 1984 MAR CRLD
\+ EQ 2GM BASE/VIAL — N62464 002 MAY 07, 1984 MAR CRLD
EQ 4GM BASE/VIAL — N62464 003 MAY 07, 1984 MAR CRLD
KEFLIN
@ LILLY
@ EQ 1GM BASE/VIAL — N50482 001 MAR DISC
@ EQ 2GM BASE/VIAL — N50482 002 MAR DISC
@ EQ 4GM BASE/VIAL — N50482 003 MAR DISC

CHLORAMPHENICOL
OINTMENT; OPHTHALMIC
CHLORAMPHENICOL
>D> AT ALTANA
>A> AT \+ 1% — N60133 001 MAY CRLD
>D> 1% — N60133 001 MAY CRLD
CHLOROMYCETIN
>D> AT \+ PARKEDALE
>A> @ 1% — N50156 001 MAY DISC
1% — N50156 001 MAY DISC
SOLUTION/DROPS; OTIC
>D> \+ PARKEDALE
>A> @ 0.5% — N50205 001 MAY DISC
0.5% — N50205 001 MAY DISC

>D> CHLOROTHIAZIDE; METHYLDOPA
>D> TABLET; ORAL
>D> ALDOCLOR-150
>D> MERCK
>A> @ 150MG;250MG — N16016 001 MAY DISC
>D> 150MG;250MG — N16016 001 MAY DISC
>D> ALDOCLOR-250
>D> \+ MERCK
>A> @ 250MG;250MG — N16016 002 MAY DISC
250MG;250MG — N16016 002 MAY DISC

CHLORTHALIDONE
TABLET; ORAL
THALITONE
>D> BX MONARCH PHARMS
>A> @ 25MG — N19574 002 FEB 12, 1992 MAY DISC
25MG — N19574 002 FEB 12, 1992 MAY DISC

CICLOPIROX
SHAMPOO; TOPICAL
LOPROX
\+ MEDICIS 1% N21159 001 FEB 28, 2003 FEB NEWA

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN
AP + ORTHO BIOTECH 1MG/ML N20229 001 FEB 26, 1993 APR CTEC

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLINDAMYCIN HCL
AB WATSON LABS EQ 300MG BASE N63083 002 MAR 18, 2003 MAR NEWA

CLONAZEPAM
TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING
ROCHE 0.125MG N20813 001 DEC 23, 1997 APR CMFD
0.25MG N20813 002 DEC 23, 1997 APR CMFD
0.5MG N20813 003 DEC 23, 1997 APR CMFD
\+ 1MG N20813 004 DEC 23, 1997 APR CMFD
2MG N20813 005 DEC 23, 1997 APR CMFD

COLESTIPOL HYDROCHLORIDE
TABLET; ORAL
COLESTID
>D> PHARMACIA AND UPJOHN 1GM N20222 001 JUL 19, 1994 MAY CRLD
>A> + 1GM N20222 001 JUL 19, 1994 MAY CRLD

COPPER
INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A
\+ FEI 309MG/COPPER N18680 001 NOV 15, 1984 MAR CAHN

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE
BP + PHARMACIA AND UPJOHN 25MG N08126 001 APR CRLD
CORTONE
@ MERCK 25MG N07750 003 APR DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
>D> CROMOPTIC
>D> AT KING PHARMS 4% N75088 001 APR 27, 1999 MAY DISC
>A> @ 4% N75088 001 APR 27, 1999 MAY DISC

CYCLOBENZAPRINE HYDROCHLORIDE
TABLET; ORAL
FLEXERIL
AA MCNEIL CONS SPECLT 5MG N17821 001 MAR CMFD

		5MG	N17821 001		APR	CTEC

CYCLOSPORINE
CAPSULE; ORAL
GENGRAF

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB	CTNA
BX		50MG	N65003 002	MAY 12, 2000	FEB	CTNA
AB1		100MG	N65003 003	MAY 12, 2000	FEB	CTNA

EMULSION; OPHTHALMIC
RESTASIS

+	ALLERGAN	0.05%	N50790 001	DEC 23, 2002	MAR	CMS1

DALFOPRISTIN; QUINUPRISTIN
INJECTABLE; IV (INFUSION)
SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB	CAHN
@		420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB	CAHN

DEMECLOCYCLINE HYDROCHLORIDE
TABLET; ORAL
DECLOMYCIN

@	WYETH PHARMS INC	75MG	N50261 001		MAR	CAHN
		150MG	N50261 002		MAR	CAHN
+		300MG	N50261 003		MAR	CAHN

DESIRUDIN
INJECTABLE; SUBCUTANEOUS
IPRIVASK

+	AVENTIS PHARMS	15MG/VIAL	N21271 001	APR 04, 2003	APR	NEWA

DESMOPRESSIN ACETATE
SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE

>A>	AB	+	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	MAY	CMS1
>D>		+		0.01MG/SPRAY	N21333 001	SEP 16, 2002	MAY	CMS1

DESOGESTREL; ETHINYL ESTRADIOL
TABLET; ORAL-21
ORTHO-CEPT

@	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001	DEC 14, 1992	MAR	DISC

TABLET; ORAL-28

AB	+	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002	DEC 14, 1992	MAR	CRLD

DEXAMETHASONE
ELIXIR; ORAL
DECADRON

@	MERCK	0.5MG/5ML	N12376 002		APR	DISC

HEXADROL

AA	+	ORGANON	0.5MG/5ML	N12674 001		APR	CRLD

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP		AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003	APR	NEWA

>D> DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
>D> SOLUTION/DROPS; OPHTHALMIC
>D> NEODECADRON

>D>	+	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001		MAY	DISC
>A>		@	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001		MAY	DISC

DEXTROAMPHETAMINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

>A>	AB	MALLINCKRODT	5MG	N76353 001	MAY 06, 2003	MAY	NEWA
>A>	AB		10MG	N76353 002	MAY 06, 2003	MAY	NEWA
>A>	AB		15MG	N76353 003	MAY 06, 2003	MAY	NEWA

>D> DICHLORPHENAMIDE
>D> TABLET; ORAL
>D> DARANIDE

>D>	+	MERCK	50MG	N11366 001		MAY	DISC
>A>		@	50MG	N11366 001		MAY	DISC

DIGOXIN
TABLET; ORAL
DIGOXIN

AB		CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
AB			0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE
INJECTABLE; INJECTION
D.H.E. 45

AP	+	XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG

DIHYDROEROGTAMINE MESYLATE

AP		PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
TAZTIA XT

AB4		ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
AB4			180MG	N75401 002	APR 10, 2003	APR	NEWA
AB4			240MG	N75401 003	APR 10, 2003	APR	NEWA
AB4			300MG	N75401 004	APR 10, 2003	APR	NEWA
AB4			360MG	N75401 005	APR 10, 2003	APR	NEWA

TIAZAC

AB4	+	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
AB4	+		180MG	N20401 002	SEP 11, 1995	APR	CFTG
AB4	+		240MG	N20401 003	SEP 11, 1995	APR	CFTG
AB4	+		300MG	N20401 004	SEP 11, 1995	APR	CFTG
AB4	+		360MG	N20401 005	SEP 11, 1995	APR	CFTG

DILTIAZEM HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
CARDIZEM LA

	+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
	+		180MG	N21392 002	FEB 06, 2003	FEB	NEWA
	+		240MG	N21392 003	FEB 06, 2003	FEB	NEWA
	+		300MG	N21392 004	FEB 06, 2003	FEB	NEWA
	+		360MG	N21392 005	FEB 06, 2003	FEB	NEWA
	+		420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DILTIAZEM MALATE
TABLET, EXTENDED RELEASE; ORAL
TIAMATE

>D>	+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
>A>	@		EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
>D>	+		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
>A>	@		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
>D>	+		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC
>A>	@		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC

DOXAPRAM HYDROCHLORIDE
INJECTABLE; INJECTION
DOPRAM

AP	+	BAXTER HLTHCARE CORP	20MG/ML	N14879 001		JAN	CAHN

DOXAPRAM HCL

AP		BEDFORD	20MG/ML	N76266 001	JAN 10, 2003	JAN	NEWA

DOXYCYCLINE
CAPSULE; ORAL
DOXYCYCLINE

>A>	AB	AXIOM PHARM	EQ 50MG BASE	N65041 001	APR 28, 2000	MAY	CAHN
>A>	AB		EQ 100MG BASE	N65041 002	APR 28, 2000	MAY	CAHN
>D>	AB	HALSEY	EQ 50MG BASE	N65041 001	APR 28, 2000	MAY	CAHN
>D>	AB		EQ 100MG BASE	N65041 002	APR 28, 2000	MAY	CAHN

DOXYCYCLINE HYCLATE
CAPSULE; ORAL
DOXYCYCLINE HYCLATE

>A>	AB	AXIOM PHARM	EQ 50MG BASE	N61717 001		MAY	CAHN
>A>	AB		EQ 100MG BASE	N61717 002		MAY	CAHN
>D>	AB	HALSEY	EQ 50MG BASE	N61717 001		MAY	CAHN
>D>	AB		EQ 100MG BASE	N61717 002		MAY	CAHN

CAPSULE, COATED PELLETS; ORAL
DORYX

		FAULDING	EQ 75MG BASE	N50582 002	AUG 13, 2001	FEB	NEWA

INJECTABLE; INJECTION
DOXY 100

	+	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983	MAR	CRLD

DOXY 200

	+	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983	MAR	CRLD

		DOXYCYCLINE HYCLATE						
		INJECTABLE; INJECTION						
		VIBRAMYCIN						
		@ PFIZER	EQ 100MG BASE/VIAL	N50442 002			MAR	DISC
		@	EQ 200MG BASE/VIAL	N50442 001			MAR	DISC
		TABLET; ORAL						
		DOXYCYCLINE HYCLATE						
>A>	AB	AXIOM PHARM	EQ 100MG BASE	N62269 002	NOV 08, 1982		MAY	CAHN
>D>	AB	HALSEY	EQ 100MG BASE	N62269 002	NOV 08, 1982		MAY	CAHN
		DOXYCYCLINE HYLATE						
>A>		@ AXIOM PHARM	EQ 50MG BASE	N62269 003			MAY	CAHN
>D>		@ HALSEY	EQ 50MG BASE	N62269 003			MAY	CAHN
		EDROPHONIUM CHLORIDE						
		INJECTABLE; INJECTION						
>D>		REVERSOL						
>D>	AP	ORGANON	10MG/ML	N89624 001	MAY 13, 1988		MAY	DISC
>A>		@	10MG/ML	N89624 001	MAY 13, 1988		MAY	DISC
		ELETRIPTAN HYDROBROMIDE						
		TABLET; ORAL						
		RELPAX						
		PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002		MAR	CAHN
	+		EQ 40MG BASE	N21016 002	DEC 26, 2002		MAR	CAHN
		ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE						
		TABLET; ORAL						
		ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE						
	AB	IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003		MAR	NEWA
	AB		10MG;25MG	N75736 002	MAR 25, 2003		MAR	NEWA
		ENFUVIRTIDE						
		INJECTABLE; SUBCUTANEOUS						
		FUZEON						
	+	ROCHE	90MG/VIAL	N21481 001	MAR 13, 2003		MAR	NEWA
		ENOXAPARIN SODIUM						
		INJECTABLE; SUBCUTANEOUS						
		LOVENOX						
	+	AVENTIS	300MG/3ML	N20164 009	JAN 23, 2003		JAN	NEWA
		EPINEPHRINE						
>A>		INJECTABLE; IM-SC						
>A>		TWINJECT						
>A>	+	HOLLISTER STIER LABS	0.3MG /DELIVERY	N20800 001	MAY 30, 2003		MAY	NEWA
		EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DURANEST						
		@ DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001			MAR	DISC

	ERGOTAMINE TARTRATE						
	TABLET; SUBLINGUAL						
	ERGOMAR						
	+ HARVEST PHARMS	2MG	N87693 001	FEB 24, 1983	MAR	CAHN
	ERYTHROMYCIN						
	SOLUTION; TOPICAL						
	STATICIN						
	+ WESTWOOD SQUIBB	1.5%	N50526 001		APR	CTEC
	ESMOLOL HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+ BAXTER HLTHCARE CORP	2GM/100ML	N19386 005	JAN 27, 2003	MAR	NEWA
	BREVIBLOC IN PLASTIC CONTAINER						
	+ BAXTER HLTHCARE CORP	1GM/100ML	N19386 004	FEB 16, 2001	MAR	NEWA
	ESTRADIOL ACETATE						
	INSERT, EXTENDED RELEASE; VAGINAL						
	FEMRING						
	GALEN LTD	0.05MG/24HR	N21367 001	MAR 20, 2003	MAR	NEWA
	+	0.1MG/24HR	N21367 002	MAR 20, 2003	MAR	NEWA
>D>	ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE						
>D>	INJECTABLE; INJECTION						
>D>	DEPO-TESTADIOL						
>D>	+ PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N17968 001		MAY	WDAG
>A>	@	2MG/ML;50MG/ML	N17968 001		MAY	WDAG
	ESTRADIOL; NORGESTIMATE						
	TABLET; ORAL						
>D>	ORTHO-PREFEST						
>D>	+ KING PHARMS	1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CTNA
>A>	PREFEST						
>A>	+ KING PHARMS	1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CTNA
	ESTROGENS, CONJUGATED						
	CREAM; TOPICAL, VAGINAL						
	PREMARIN						
	+ WYETH PHARMS INC	0.625MG/GM	N20216 001		MAR	CAHN
	INJECTABLE; INJECTION						
	+ WYETH PHARMS INC	25MG/VIAL	N10402 001		MAR	CAHN
	TABLET; ORAL						
	WYETH PHARMS INC	0.3MG	N04782 003		MAR	CAHN
	+	0.625MG	N04782 004		MAR	CAHN
		0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
	+	1.25MG	N04782 001		MAR	CAHN
		2.5MG	N04782 002		MAR	CAHN
	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
	TABLET; ORAL-28						
	PREMPHASE (PREMARIN;CYCRIN 14/14)						
	@ WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+	WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20527 002	NOV 17, 1995	MAR	CAHN

PREMPRO

+	WYETH PHARMS INC	0.45MG;1.5MG	N20527 004	MAR 12, 2003	MAR	NEWA
+		0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	MAR	CAHN
+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	MAR	CAHN

PREMPRO (PREMARIN;CYCRIN)

@	WYETH PHARMS INC	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	MAR	CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

	MONARCH PHARMS	0.3MG	N84951 001		JAN	CRLD

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN

>D>	MERCK	25MG	N16092 001		MAY	CRLD
>A>	+	25MG	N16092 001		MAY	CRLD
>D>	+	50MG	N16092 002		MAY	DISC
>A>	@	50MG	N16092 002		MAY	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB1 +	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003	APR	NEWA

NORDETTE-21

AB +	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982	MAR	CAHN

TRIPHASIL-21

AB +	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG;0.075MG	N19192 001	NOV 01, 1984	MAR	CAHN

TABLET; ORAL-28

ALESSE

AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003	APR	NEWA

NORDETTE-28

AB	WYETH PHARMS INC	0.03MG;0.15MG	N18782 001	JUL 21, 1982	MAR	CAHN

TRIPHASIL-28

AB	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG;0.075MG	N19190 001	NOV 01, 1984	MAR	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

TRI-NORINYL 21-DAY

@	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977 001	APR 13, 1984	MAR	CPOT

		@	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984	FEB	DISC	
		TABLET; ORAL-28						
		ORTHO-NOVUM 7/7/7-28						
	AB	+ ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002	APR 04, 1984	FEB	CRLD	
		OVCON-35						
		+ WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		JAN	CRLD	
		OVCON-50						
		+ WARNER CHILCOTT	0.05MG;1MG	N17576 001		JAN	CRLD	
		TRI-NORINYL 28-DAY						
		+ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977 002	APR 13, 1984	MAR	CPOT	
		+	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984	JAN	CRLD	
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE						
		TABLET; ORAL						
		FEMHRT						
>A>		+ GALEN CHEM	0.005MG;1MG	N21065 002	OCT 15, 1999	MAY	CAHN	
>D>		+ PFIZER PHARMS	0.005MG;1MG	N21065 002	OCT 15, 1999	MAY	CAHN	
		TABLET; ORAL-21						
		ESTROSTEP 21						
		@ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	APR	CAHN	
>A>		JUNEL 1.5/30						
>A>	AB	BARR	0.03MG;1.5MG	N76381 001	MAY 30, 2003	MAY	NEWA	
>A>		JUNEL 1/20						
>A>	AB	BARR	0.02MG;1MG	N76380 001	MAY 30, 2003	MAY	NEWA	
		LOESTRIN 21 1.5/30						
>D>		+ GALEN CHEM	0.03MG;1.5MG	N17875 001		MAY	CFTG	
>A>	AB	+	0.03MG;1.5MG	N17875 001		MAY	CFTG	
		+	0.03MG;1.5MG	N17875 001		APR	CAHN	
		LOESTRIN 21 1/20						
>D>		+ GALEN CHEM	0.02MG;1MG	N17876 001		MAY	CFTG	
>A>	AB	+	0.02MG;1MG	N17876 001		MAY	CFTG	
		+	0.02MG;1MG	N17876 001		APR	CAHN	
		TABLET; ORAL-28						
		ESTROSTEP FE						
		+ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 002	OCT 09, 1996	APR	CAHN	
		LOESTRIN FE 1.5/30						
	AB	+ GALEN CHEM	0.03MG;1.5MG	N17355 001		APR	CAHN	
		LOESTRIN FE 1/20						
	AB	+ GALEN CHEM	0.02MG;1MG	N17354 001		APR	CAHN	
		ETHINYL ESTRADIOL; NORGESTREL						
		TABLET; ORAL-21						
		LO/OVRAL						
	AB	+ WYETH PHARMS INC	0.03MG;0.3MG	N17612 001		MAR	CAHN	
		OGESTREL 0.5/50-21						
	AB	WATSON LABS	0.05MG;0.5MG	N75406 001	DEC 15, 1999	FEB	CAHN	
		OVRAL						
	AB	+ WYETH PHARMS INC	0.05MG;0.5MG	N16672 001		MAR	CAHN	
		TABLET; ORAL-28						
		LO/OVRAL-28						
	AB	WYETH PHARMS INC	0.03MG;0.3MG	N17802 001		MAR	CAHN	

ETHINYL ESTRADIOL; NORGESTREL							
TABLET; ORAL-28							
OGESTREL 0.5/50-28							
AB	WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999	FEB	CAHN
OVRAL-28							
AB	WYETH PHARMS INC	0.05MG;0.5MG	N16806 001		MAR	CAHN
ETHIONAMIDE							
TABLET; ORAL							
TRECATOR-SC							
+	WYETH PHARMS INC	250MG	N13026 002		MAR	CAHN
ETHOTOIN							
TABLET; ORAL							
PEGANONE							
+	OVATION PHARMS	250MG	N10841 001		MAR	CAHN
@		500MG	N10841 003		MAR	CAHN
ETIDRONATE DISODIUM							
TABLET; ORAL							
ETIDRONATE DISODIUM							
AB	GENPHARM	200MG	N75800 001	JAN 24, 2003	JAN	NEWA
AB		400MG	N75800 002	JAN 24, 2003	JAN	NEWA
ETODOLAC							
CAPSULE; ORAL							
LODINE							
AB	WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991	MAR	CAHN
AB +		300MG	N18922 003	JAN 31, 1991	MAR	CAHN
TABLET; ORAL							
AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993	MAR	CAHN
AB +		500MG	N18922 005	JUN 28, 1996	MAR	CAHN
TABLET, EXTENDED RELEASE; ORAL							
ETODOLAC							
AB	TARO	400MG	N76174 001	MAR 13, 2003	MAR	NEWA
AB		500MG	N76174 002	MAR 13, 2003	MAR	NEWA
AB		600MG	N76174 003	MAR 13, 2003	MAR	NEWA
LODINE XL							
AB +	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996	MAR	CAHN
AB +		500MG	N20584 003	JAN 20, 1998	MAR	CAHN
AB +		600MG	N20584 002	OCT 25, 1996	MAR	CAHN
FELBAMATE							
SUSPENSION; ORAL							
FELBATOL							
+	MEDPOINTE	600MG/5ML	N20189 003	JUL 29, 1993	MAR	CAHN
TABLET; ORAL							
MEDPOINTE		400MG	N20189 001	JUL 29, 1993	MAR	CAHN
+		600MG	N20189 002	JUL 29, 1993	MAR	CAHN

FENOFIBRATE
CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

		TEVA	67MG	N75753	001	SEP 03, 2002	MAR	CTEC
			134MG	N75753	002	APR 09, 2002	MAR	CTEC
	+		200MG	N75753	003	APR 09, 2002	MAR	CRLD

TRICOR (MICRONIZED)

		@ ABBOTT	67MG	N19304	002	FEB 09, 1998	MAR	DISC
		@	134MG	N19304	003	JUN 30, 1999	MAR	DISC
		@	200MG	N19304	004	JUN 30, 1999	MAR	DISC

FLAVOXATE HYDROCHLORIDE
TABLET; ORAL
URISPAS

	+	ORTHO-MCNEIL PHARMAC	100MG	N16769	001		MAR	CAHN

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE

	AB	RANBAXY	50MG	N76421	001	MAR 28, 2003	MAR	NEWA
	AB		100MG	N76421	002	MAR 28, 2003	MAR	NEWA
	AB		150MG	N76421	003	MAR 28, 2003	MAR	NEWA
	AB	ROXANE	50MG	N76278	001	JAN 14, 2003	JAN	NEWA
	AB		100MG	N76278	002	JAN 14, 2003	JAN	NEWA
	AB		150MG	N76278	003	JAN 14, 2003	JAN	NEWA

FLUDROCORTISONE ACETATE
TABLET; ORAL
FLUDROCORTISONE ACETATE

	AB	BARR	0.1MG	N40425	001	JAN 21, 2003	JAN	NEWA

FLUOCINONIDE
CREAM; TOPICAL
FLUOCINONIDE

>D>	AB	ALPHARMA US PHARM	0.05%	N73085	001	FEB 14, 1992	MAY	CTEC
>A>	AB1		0.05%	N73085	001	FEB 14, 1992	MAY	CTEC
>D>	AB	FOUGERA	0.05%	N73030	001	OCT 17, 1994	MAY	CTEC
>A>	AB1		0.05%	N73030	001	OCT 17, 1994	MAY	CTEC
>D>	AB	TARO	0.05%	N19117	001	JUN 26, 1984	MAY	CTEC
>A>	AB1		0.05%	N19117	001	JUN 26, 1984	MAY	CTEC
>D>	AB		0.05%	N71500	001	JUN 10, 1987	MAY	CTEC
>A>	AB1		0.05%	N71500	001	JUN 10, 1987	MAY	CTEC
>D>	AB	TEVA	0.05%	N72488	001	FEB 06, 1989	MAY	CTEC
>A>	AB1		0.05%	N72488	001	FEB 06, 1989	MAY	CTEC

FLUOCINONIDE EMULSIFIED BASE

>D>	AB	ALPHARMA US PHARM	0.05%	N74204	001	JUN 13, 1995	MAY	CTEC
>A>	AB2		0.05%	N74204	001	JUN 13, 1995	MAY	CTEC
>D>	AB	DRAXIS HLTH	0.05%	N72494	001	JAN 19, 2089	MAY	CTEC
>A>	AB2		0.05%	N72494	001	JAN 19, 2089	MAY	CTEC
>D>	AB	TEVA	0.05%	N72490	001	FEB 07, 1989	MAY	CTEC
>A>	AB2		0.05%	N72490	001	FEB 07, 1989	MAY	CTEC

FLUOCINONIDE
CREAM; TOPICAL
LIDEX

>D>	AB	+	MEDICIS	0.05%	N16908 002		MAY	CTEC
>A>	AB1	+		0.05%	N16908 002		MAY	CTEC

LIDEX-E

>D>	AB		MEDICIS	0.05%	N16908 003		MAY	CRLD
>A>	AB2	+		0.05%	N16908 003		MAY	CRLD

FLUORESCEIN SODIUM
INJECTABLE; INJECTION
FUNDUSCEIN-25

			@ NOVARTIS	25%	N17869 001		JAN	DISC

FLUPHENAZINE DECANOATE
INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

>D>	AO		KING PHARMS	25MG/ML	N74966 001	APR 16, 1998	MAY	DISC
>A>			@	25MG/ML	N74966 001	APR 16, 1998	MAY	DISC

FLURANDRENOLIDE
LOTION; TOPICAL
CORDRAN

>D>	AT	+	OCLASSEN	0.05%	N13790 001		MAY	CTEC
>A>		+		0.05%	N13790 001		MAY	CTEC

FLUTAMIDE
CAPSULE; ORAL
FLUTAMIDE

>A>	AB		GENPHARM	125MG	N76224 001	MAY 09, 2003	MAY	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

	AB		GENEVA PHARMS	25MG	N75887 001	JAN 05, 2001	APR	CAHN
	AB			50MG	N75887 002	JAN 05, 2001	APR	CAHN
	AB			100MG	N75887 003	JAN 05, 2001	APR	CAHN

FOLIC ACID
INJECTABLE; INJECTION
FOLVITE

	AP	+	WYETH PHARMS INC	5MG/ML	N05897 008		MAR	CAHN

TABLET; ORAL

			@ WYETH PHARMS INC	1MG	N05897 004		MAR	CAHN

GALANTAMINE HYDROBROMIDE
TABLET; ORAL
REMINYL

		+	JANSSEN PHARMA	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
				EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

		GATIFLOXACIN					
		INJECTABLE; INJECTION					
		TEQUIN					
	+	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
	+		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
	+		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD
		SOLUTION/DROPS; OPHTHALMIC					
		ZYMAR					
	+	ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA
>A>		GEFITINIB					
>A>		TABLET; ORAL					
>A>		IRESSA					
>A>	+	ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA
		GEMIFLOXACIN MESYLATE					
		TABLET; ORAL					
		FACTIVE					
>A>	+	GENESOFT PHARMS	EQ 320MG BASE	N21158 001	APR 04, 2003	MAY	CAHN
>D>	+	LG LIFE	EQ 320MG BASE	N21158 001	APR 04, 2003	MAY	CAHN
	+		EQ 320MG BASE	N21158 001	APR 04, 2003	APR	NEWA
		GEMTUZUMAB OZOGAMICIN					
		INJECTABLE; INJECTION					
		MYLOTARG					
	+	WYETH PHARMS INC	5MG/VIAL	N21174 001	MAY 17, 2000	MAR	CAHN
		GENTAMICIN SULFATE					
		CREAM; TOPICAL					
		GARAMYCIN					
	@	SCHERING	EQ 0.1% BASE	N60462 001		FEB	DISC
		GENTAMICIN SULFATE					
AT	+	FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984	FEB	CRLD
		OINTMENT; OPHTHALMIC					
		GARAMYCIN					
	@	SCHERING	EQ 0.3% BASE	N50425 001		APR	DISC
		GENTAMICIN SULFATE					
	+	AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD
		GLIMEPIRIDE					
		TABLET; ORAL					
		AMARYL					
	+	AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995	JAN	CRLD
			4MG	N20496 003	NOV 30, 1995	JAN	CRLD
		GONADORELIN HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		FACTREL					
>A>	+	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN
>A>	@		EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN
>A>	@		EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN
>D>	+	WYETH AYERST	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN

>D>		@	EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN
>D>		@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN
>D>		GREPAFLOXACIN HYDROCHLORIDE					
>D>		TABLET; ORAL					
>D>		RAXAR					
>D>		OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
>A>		@	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
>D>			EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
>A>		@	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
>D>		+	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC
>A>		@	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC
		HALOPERIDOL DECANOATE					
		INJECTABLE; INJECTION					
		HALOPERIDOL DECANOATE					
>D>	AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
>A>		@	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
>D>	AO		EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC
>A>		@	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC
		HEPARIN SODIUM					
		INJECTABLE; INJECTION					
		HEPARIN LOCK FLUSH					
>A>		@ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN
>A>		@	100 UNITS/ML	N17007 009		MAY	CAHN
>D>		@ WYETH AYERST	10 UNITS/ML	N17007 008		MAY	CAHN
>D>		@	100 UNITS/ML	N17007 009		MAY	CAHN
		HEPARIN SODIUM					
>A>		@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN
>A>		@	2,500 UNITS/ML	N17007 007		MAY	CAHN
>A>		@	5,000 UNITS/ML	N17007 002		MAY	CAHN
>A>		@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
>A>		@	7,500 UNITS/ML	N17007 003		MAY	CAHN
>A>		@	10,000 UNITS/ML	N17007 004		MAY	CAHN
>A>		@	15,000 UNITS/ML	N17007 005		MAY	CAHN
>A>		@	20,000 UNITS/ML	N17007 006		MAY	CAHN
>D>		@ WYETH AYERST	1,000 UNITS/ML	N17007 001		MAY	CAHN
>D>		@	2,500 UNITS/ML	N17007 007		MAY	CAHN
>D>		@	5,000 UNITS/ML	N17007 002		MAY	CAHN
>D>		@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
>D>		@	7,500 UNITS/ML	N17007 003		MAY	CAHN
>D>		@	10,000 UNITS/ML	N17007 004		MAY	CAHN
>D>		@	15,000 UNITS/ML	N17007 005		MAY	CAHN
>D>		@	20,000 UNITS/ML	N17007 006		MAY	CAHN
		HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE					
		SYRUP; ORAL					
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
>A>	AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN
>D>	AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL
INDERIDE-40/25

AB		WYETH PHARMS INC	25MG;40MG	N18031 001		MAR	CAHN

INDERIDE-80/25

AB	+	WYETH PHARMS INC	25MG;80MG	N18031 002		MAR	CAHN

HYDROCODONE BITARTRATE; IBUPROFEN
TABLET; ORAL
HYDROCODONE BITARTRATE AND IBUPROFEN

AB		TEVA	7.5MG;200MG	N76023 001	APR 11, 2003	APR	NEWA

VICOPROFEN

AB	+	ABBOTT	7.5MG;200MG	N20716 001	SEP 23, 1997	APR	CFTG

HYDROCORTISONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
HYDROCORTONE

		@ MERCK	EQ 50MG BASE/ML	N12052 001		APR	DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT		ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	FEB	CMFD

SUSPENSION/DROPS; OPHTHALMIC

AT		ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	FEB	CMFD

SUSPENSION/DROPS; OTIC

AT		ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	FEB	CMFD

HYDROMORPHONE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP		FAULDING	10MG/ML	N76444 001	APR 25, 2003	APR	NEWA

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
ATARAX

		@ PFIZER	10MG	N10392 001		FEB	DISC
		@	25MG	N10392 004		FEB	DISC
		@	50MG	N10392 006		FEB	DISC
		@	100MG	N10392 005		FEB	DISC

HYDROXYZINE HCL

AB	+	SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB	CRLD
AB	+		25MG	N88618 001	JAN 10, 1986	FEB	CRLD
AB	+		50MG	N88619 001	JAN 10, 1986	FEB	CRLD
		@	100MG	N81054 001	SEP 25, 1995	FEB	DISC

>A> IBANDRONATE SODIUM
>A> TABLET; ORAL
>A> BONIVA

>A>	+	ROCHE	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	MAY	NEWA

IMATINIB MESYLATE
TABLET; ORAL
GLEEVEC

		NOVARTIS	100MG	N21588 001	APR 18, 2003	APR	NEWA
	+		400MG	N21588 002	APR 18, 2003	APR	NEWA

IPRATROPIUM BROMIDE
SPRAY, METERED; NASAL
ATROVENT

AB	+	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
AB	+		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG

IPRATROPIUM BROMIDE

AB		BAUSCH AND LOMB	0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA
AB		DEY	0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
AB		NOVEX	0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
AB			0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA

ISONIAZID
TABLET; ORAL
ISONIAZID

>A>		@ AXIOM PHARM	100MG	N80136 001		MAY	CAHN
>A>	AA		300MG	N83633 001		MAY	CAHN
>D>		@ HALSEY	100MG	N80136 001		MAY	CAHN
>D>	AA		300MG	N83633 001		MAY	CAHN

ISOSORBIDE DINITRATE
TABLET; ORAL
ISORDIL

AB		WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
AB			10MG	N12093 002	JUL 29, 1988	MAR	CAHN
AB			20MG	N12093 006	JUL 29, 1988	MAR	CAHN
AB	+		30MG	N12093 005	JUL 29, 1988	MAR	CAHN
AB			40MG	N12093 001	JUL 29, 1988	MAR	CAHN

TABLET; SUBLINGUAL

AB		WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
AB			5MG	N12940 003	JUL 29, 1988	MAR	CAHN
	+		10MG	N12940 005	JUL 29, 1988	MAR	CAHN

ISOTRETINOIN
CAPSULE; ORAL
CLARAVIS

AB		BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB			20MG	N76135 002	APR 11, 2003	APR	NEWA
AB			40MG	N76135 001	APR 11, 2003	APR	NEWA

ISRADIPINE
CAPSULE; ORAL
DYNACIRC

>D>		NOVARTIS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
>D>	+		5MG	N19546 002	DEC 20, 1990	MAY	CAHN

>A>		RELIANT PHARMS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
>A>	+		5MG	N19546 002	DEC 20, 1990	MAY	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	DYNACIRC CR						
>D>	+	NOVARTIS	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
>D>	+		10MG	N20336 002	JUN 01, 1994	MAY	CAHN
>A>	+	RELIANT PHARMS	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
>A>	+		10MG	N20336 002	JUN 01, 1994	MAY	CAHN
KETOPROFEN							
CAPSULE, EXTENDED RELEASE; ORAL							
ORUVAIL							
AB		WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN
AB			150MG	N19816 002	FEB 08, 1995	MAR	CAHN
AB	+		200MG	N19816 001	SEP 24, 1993	MAR	CAHN
KETOROLAC TROMETHAMINE							
SOLUTION/DROPS; OPHTHALMIC							
>A>		ACULAR LS					
>A>	+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003	MAY	NEWA
LACTULOSE							
SOLUTION; ORAL							
LACTULOSE							
AA		VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992	MAR	CAHN
LEFLUNOMIDE							
TABLET; ORAL							
ARAVA							
+		AVENTIS PHARMS	20MG	N20905 002	SEP 10, 1998	MAR	CRLD
@			100MG	N20905 003	SEP 10, 1998	MAR	DISC
LEUPROLIDE ACETATE							
INJECTABLE; SUBCUTANEOUS							
ELIGARD							
+		ATRIX	30MG/VIAL	N21488 001	FEB 13, 2003	FEB	NEWA
LEVOBETAXOLOL HYDROCHLORIDE							
SUSPENSION/DROPS; OPHTHALMIC							
BETAXON							
+		MEDPOINTE	EQ 0.5% BASE	N21114 001	FEB 23, 2000	MAR	CAHN
LEVONORGESTREL							
IMPLANT; IMPLANTATION							
LEVONORGESTREL							
BX	+	WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
NORPLANT SYSTEM IN PLASTIC CONTAINER							
+		WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN
LEVORPHANOL TARTRATE							
TABLET; ORAL							
LEVO-DROMORAN							
@		ICN	2MG	N08720 001	DEC 19, 1991	FEB	DISC

LEVORPHANOL TARTRATE
TABLET; ORAL
LEVORPHANOL TARTRATE

+	ROXANE	2MG	N74278 001	MAR 31, 2000	FEB	CRLD

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVO-T

BX	ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN
BX		0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
BX		0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
BX		0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
BX		0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
BX		0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
BX		0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
BX		0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
BX		0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
BX		0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
BX +		0.3MG	N21342 011	MAR 01, 2002	APR	CAHN

LIDOCAINE HYDROCHLORIDE
JELLY; TOPICAL
LIDOCAINE HCL

AT	AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA

LISINOPRIL
TABLET; ORAL
LISINOPRIL

AB	RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA

ZESTRIL

AB	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE
CAPSULE; ORAL
LITHIUM CARBONATE

AB	ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB	WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA

TABLET, EXTENDED RELEASE; ORAL

AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA

>D>	LORATADINE						
>D>	SYRUP; ORAL						
>D>	CLARITIN						
>D>	+ SCHERING	1MG/ML	N20641 001	OCT 10, 1996	MAY	DISC
>A>	@	1MG/ML	N20641 001	OCT 10, 1996	MAY	DISC
>D>	TABLET; ORAL						
>D>	+ SCHERING	10MG	N19658 001	APR 12, 1993	MAY	DISC
>A>	@	10MG	N19658 001	APR 12, 1993	MAY	DISC
>D>	TABLET, ORALLY DISINTEGRATING; ORAL						
>D>	CLARITIN REDITABS						
>D>	+ SCHERING	10MG	N20704 001	DEC 23, 1996	MAY	DISC

>A>		@	10MG	N20704 001	DEC 23, 1996	MAY	DISC

LORAZEPAM
CONCENTRATE; ORAL
LORAZEPAM INTENSOL

>D>			ROXANE	2MG/ML	N72755 001	JUN 28, 1991	MAY	CRLD
>A>		+		2MG/ML	N72755 001	JUN 28, 1991	MAY	CRLD

INJECTABLE; INJECTION
ATIVAN

	AP	+	BAXTER HLTHCARE CORP	2MG/ML	N18140 001		FEB	CAHN
	AP	+		4MG/ML	N18140 002		FEB	CAHN

MECAMYLAMINE HYDROCHLORIDE
TABLET; ORAL
INVERSINE

		+	TARGACEPT	2.5MG	N10251 001		APR	CAHN

MECLOFENAMATE SODIUM
CAPSULE; ORAL
MECLOFENAMATE SODIUM

>D>	AB		MYLAN	EQ 100MG BASE	N71081 001	SEP 03, 1986	MAY	CRLD
>A>	AB	+		EQ 100MG BASE	N71081 001	SEP 03, 1986	MAY	CRLD
>D>			MECLOMEN					
>D>	AB		PARKE DAVIS	EQ 50MG BASE	N18006 001		MAY	DISC
>A>			@	EQ 50MG BASE	N18006 001		MAY	DISC
>D>	AB	+		EQ 100MG BASE	N18006 002		MAY	DISC
>A>			@	EQ 100MG BASE	N18006 002		MAY	DISC

MEFLOQUINE HYDROCHLORIDE
TABLET; ORAL
MEFLOQUINE HCL

	AB		GENEVA PHARMS	250MG	N76175 001	FEB 20, 2002	APR	CAHN

MEGESTROL ACETATE
SUSPENSION; ORAL
MEGESTROL ACETATE

>A>	AB		COPLEY PHARM	40MG/ML	N75681 001	MAY 05, 2003	MAY	NEWA

MENOTROPINS (FSH;LH)
INJECTABLE; INJECTION
REPRONEX

>D>	BX		FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	MAY	CRLD
>A>	BX	+		75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	MAY	CRLD
>D>		+		150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	MAY	DISC
>A>			@	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	MAY	DISC

MEPERIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPERIDINE HCL

>A>	AP		BAXTER HLTHCARE CORP	25MG/ML	N80455 007		MAY	CAHN
>A>	AP			50MG/ML	N80455 008		MAY	CAHN
>A>	AP			75MG/ML	N80455 009		MAY	CAHN
>A>	AP			100MG/ML	N80455 010		MAY	CAHN

>D>	AP	WYETH AYERST	25MG/ML	N80455 007		MAY	CAHN
>D>	AP		50MG/ML	N80455 008		MAY	CAHN
>D>	AP		75MG/ML	N80455 009		MAY	CAHN
>D>	AP		100MG/ML	N80455 010		MAY	CAHN
		TABLET; ORAL					
>A>	AA	AXIOM PHARM	50MG	N80448 001		MAY	CAHN
>A>	AA		100MG	N80448 002		MAY	CAHN
>D>	AA	HALSEY	50MG	N80448 001		MAY	CAHN
>D>	AA		100MG	N80448 002		MAY	CAHN
		MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		MEPERGAN					
>A>		@ BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N11730 001		MAY	CAHN
>D>		@ WYETH AYERST	25MG/ML;25MG/ML	N11730 001		MAY	CAHN
		MEPHENTERMINE SULFATE					
		INJECTABLE; INJECTION					
		WYAMINE SULFATE					
		@ BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N08248 002		FEB	CAHN
		@	EQ 30MG BASE/ML	N08248 001		FEB	CAHN
		MEPROBAMATE					
		TABLET; ORAL					
		MILTOWN					
AA	+	MEDPOINTE	600MG	N83919 001		APR	CAHN
		METFORMIN HYDROCHLORIDE					
		TABLET; ORAL					
		METFORMIN HCL					
AB		PUREPAC PHARM	1GM	N76033 003	JAN 24, 2002	FEB	CMS1
		TABLET, EXTENDED RELEASE; ORAL					
		GLUCOPHAGE XR					
	+	BRISTOL MYERS SQUIBB	750MG	N21202 004	APR 11, 2003	APR	NEWA
		METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE					
		TABLET; ORAL					
		AVANDAMET					
		SB PHARMCO	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	APR	CAHN
			500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	APR	CAHN
	+		500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	APR	CAHN
		METHADONE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		DOLOPHINE HCL					
	+	AAIPHARMA	10MG/ML	N21624 001		APR	CAHN
	+	ROXANE	10MG/ML	N21624 001		FEB	CMS1
		METHOCARBAMOL					
		TABLET; ORAL					
		METHOCARBAMOL					
AA		ABLE	500MG	N40413 001	MAR 17, 2003	MAR	NEWA
AA			750MG	N40413 002	MAR 17, 2003	MAR	NEWA

	AA		LANNETT	500MG	N84756 002	MAR 31, 2003	MAR	NEWA
	AA		VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003	JAN	NEWA
	AA			750MG	N40489 002	JAN 29, 2003	JAN	NEWA
			METHOTREXATE SODIUM					
			INJECTABLE; INJECTION					
			METHOTREXATE LPF					
	AP	+	WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR	CAHN
			METHOTREXATE SODIUM					
			@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR	CAHN
		+		EQ 20MG BASE/VIAL	N11719 001		MAR	CAHN
	AP	+		EQ 25MG BASE/ML	N11719 005		MAR	CAHN
		@		EQ 50MG BASE/VIAL	N11719 003		MAR	CAHN
		@		EQ 100MG BASE/VIAL	N11719 006		MAR	CAHN
			METHOTREXATE SODIUM PRESERVATIVE FREE					
	AP	+	WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR	CAHN
			METHSCOPOLAMINE BROMIDE					
			TABLET; ORAL					
			PAMINE FORTE					
		+	BRADLEY PHARMS	5MG	N08848 002	MAR 25, 2003	MAR	NEWA
			METHYLDOPA					
			TABLET; ORAL					
			ALDOMET					
>D>	AB		MERCK	125MG	N13400 003		MAY	DISC
>A>		@		125MG	N13400 003		MAY	DISC
>D>	AB			250MG	N13400 001		MAY	DISC
>A>		@		250MG	N13400 001		MAY	DISC
			METHYLPHENIDATE HYDROCHLORIDE					
			TABLET, CHEWABLE; ORAL					
			METHYLIN					
			MALLINCKRODT	2.5MG	N21475 001	APR 15, 2003	APR	NEWA
				5MG	N21475 002	APR 15, 2003	APR	NEWA
		+		10MG	N21475 003	APR 15, 2003	APR	NEWA
			TABLET, EXTENDED RELEASE; ORAL					
			CONCERTA					
>D>		+	ALZA	18MG	N21121 001	AUG 01, 2000	MAY	CAHN
>D>		+		27MG	N21121 004	APR 01, 2002	MAY	CAHN
>D>		+		36MG	N21121 002	AUG 01, 2000	MAY	CAHN
>D>		+		54MG	N21121 003	DEC 08, 2000	MAY	CAHN
>A>		+	MCNEIL CONS SPECLT	18MG	N21121 001	AUG 01, 2000	MAY	CAHN
>A>		+		27MG	N21121 004	APR 01, 2002	MAY	CAHN
>A>		+		36MG	N21121 002	AUG 01, 2000	MAY	CAHN
>A>		+		54MG	N21121 003	DEC 08, 2000	MAY	CAHN
			METOCLOPRAMIDE HYDROCHLORIDE					
			SOLUTION; ORAL					
			METOCLOPRAMIDE					
	AA		VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	APR	CAHN

MILRINONE LACTATE
INJECTABLE; INJECTION
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP		SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD
>A>	AP	+		EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

	AB		WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
	AB			EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN
	AB	+		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CAHN

INJECTABLE; INJECTION

		+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444 001		MAR	CAHN

TABLET; ORAL
MINOCYCLINE HCL

			PAR PHARM	EQ 50MG BASE	N65131 001	APR 16, 2003	APR	NEWA
				EQ 75MG BASE	N65131 002	APR 16, 2003	APR	NEWA
		+		EQ 100MG BASE	N65131 003	APR 16, 2003	APR	NEWA

MIRTAZAPINE
TABLET; ORAL
MIRTAZAPINE

	AB		TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
	AB			30MG	N76119 002	JAN 24, 2003	JAN	NEWA

REMERON

	AB	+	ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
	AB			30MG	N20415 002	JUN 14, 1996	JAN	CFTG

MOEXIPRIL HYDROCHLORIDE
TABLET; ORAL

>A>			MOEXIPRIL HCL					
>A>	AB		TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
>A>	AB			15MG	N76204 002	MAY 08, 2003	MAY	NEWA

UNIVASC

>D>			SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
>A>	AB			7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
>D>		+		15MG	N20312 002	APR 19, 1995	MAY	CFTG
>A>	AB	+		15MG	N20312 002	APR 19, 1995	MAY	CFTG

MOXIFLOXACIN HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VIGAMOX

		+	ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA

MUPIROCIN
OINTMENT; TOPICAL
MUPIROCIN

	BX		CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	JAN	CTEC
	BX		JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	APR	CAHN

		MYCOPHENOLATE MOFETIL							
		CAPSULE; ORAL							
		CELLCEPT							
		+ ROCHE PALO	250MG	N50722 001	MAY 03, 1995	FEB	CAHN		
		SUSPENSION; ORAL							
		+ ROCHE PALO	200MG/ML	N50759 001	OCT 01, 1998	FEB	CAHN		
		TABLET; ORAL							
		+ ROCHE PALO	500MG	N50723 001	JUN 19, 1997	FEB	CAHN		
		MYCOPHENOLATE MOFETIL HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		+ ROCHE PALO	500MG/VIAL	N50758 001	AUG 12, 1998	FEB	CAHN		
		NABUMETONE							
		TABLET; ORAL							
		NABUMETONE							
	AB	IVAX PHARMS	500MG	N76009 001	JAN 24, 2003	JAN	NEWA		
	AB		750MG	N76009 002	JAN 24, 2003	JAN	NEWA		
		NALBUPHINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		NALBUPHINE HCL							
>D>	AP	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998	MAY	DISC		
>A>		@	10MG/ML	N74471 001	MAR 19, 1998	MAY	DISC		
>D>	AP		20MG/ML	N74471 002	MAR 19, 1998	MAY	DISC		
>A>		@	20MG/ML	N74471 002	MAR 19, 1998	MAY	DISC		
		NANDROLONE DECANOATE							
		INJECTABLE; INJECTION							
>D>		DECA-DURABOLIN							
>D>	AO	+ ORGANON	50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC		
>D>	AO	+	100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC		
>D>	AO	+	200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC		
>A>		@ ORGANON USA INC	50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC		
>A>		@	100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC		
>A>		@	200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC		
		NANDROLONE DECANOATE							
>D>	AO	STERIS	50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD		
>A>		+	50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD		
>D>	AO		100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD		
>A>		+	100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD		
>D>	AO		200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD		
>A>		+	200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD		
		NAPROXEN SODIUM							
		TABLET, EXTENDED RELEASE; ORAL							
		NAPRELAN							
	AB	+ ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG		
	AB	+	EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG		
		NAPROXEN SODIUM							
	AB	ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA		
	AB		EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA		

NELFINAVIR MESYLATE
TABLET; ORAL
VIRACEPT
\+ AGOURON EQ 625MG BASE N21503 001 APR 30, 2003 APR NEWA

NITROFURANTOIN
TABLET; ORAL
FURADANTIN
@ PROCTER AND GAMBLE 50MG N08693 001 APR DISC
@ 100MG N08693 002 APR DISC
NITROFURANTOIN
@ WATSON LAB 50MG N80447 001 APR DISC
@ WHITEWORTH TOWN PLSN 100MG N84085 002 APR DISC

NITROFURAZONE
OINTMENT; TOPICAL
FURACIN
@ SHIRE PHARM 0.2% N05795 001 MAR DISC

NITROGLYCERIN
FILM, EXTENDED RELEASE; TRANSDERMAL*
NITROGLYCERIN
AB2 MYLAN TECHNOLOGIES 0.1MG/HR N75033 001 FEB 06, 1998 APR CAHN
AB2 0.2MG/HR N74609 001 AUG 30, 1996 APR CAHN
AB2 0.4MG/HR N74607 001 AUG 30, 1996 APR CAHN
AB2 0.6MG/HR N74559 001 AUG 30, 1996 APR CAHN
INJECTABLE; INJECTION
>D> TRIDIL
>D> \+ FAULDING 0.5MG/ML N18537 002 JUN 16, 1983 MAY DISC
>A> @ 0.5MG/ML N18537 002 JUN 16, 1983 MAY DISC
>D> AP \+ 5MG/ML N18537 001 MAY DISC
>A> @ 5MG/ML N18537 001 MAY DISC
OINTMENT; TRANSDERMAL
NITROGLYCERIN
\+ FOUGERA 2% N87355 001 JUL 08, 1988 APR CAHN

NIZATIDINE
CAPSULE; ORAL
NIZATIDINE
AB TORPHARM 150MG N76383 001 JAN 23, 2003 JAN NEWA
AB 300MG N76383 002 JAN 23, 2003 JAN NEWA

NOREPINEPHRINE BITARTRATE
INJECTABLE; INJECTION
LEVOPHED
AP \+ ABBOTT EQ 1MG BASE/ML N07513 001 MAR CFTG
NOREPINEPHRINE BITARTRATE
AP GENSIA SICOR PHARMS EQ 1MG BASE/ML N40455 001 MAR 03, 2003 MAR NEWA

* SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL

		NORETHINDRONE ACETATE						
		TABLET; ORAL						
		AYGESTIN						
	AB	+ WYETH PHARMS INC	5MG	N18405 001	APR 21, 1982	MAR	CAHN	
		NORFLOXACIN						
>D>		SOLUTION/DROPS; OPHTHALMIC						
>D>		CHIBROXIN						
>D>		+ MERCK	0.3%	N19757 001	JUN 17, 1991	MAY	DISC	
>A>		@	0.3%	N19757 001	JUN 17, 1991	MAY	DISC	
		NORGESTREL						
		TABLET; ORAL						
		OVRETTE						
		+ WYETH PHARMS INC	0.075MG	N17031 001		MAR	CAHN	
		OLANZAPINE						
		TABLET; ORAL						
		ZYPREXA						
>D>		LILLY	5MG	N20592 002	SEP 30, 1996	MAY	CRLD	
>A>		+	5MG	N20592 002	SEP 30, 1996	MAY	CRLD	
>D>		+	20MG	N20592 006	SEP 09, 1997	MAY	CRLD	
>A>			20MG	N20592 006	SEP 09, 1997	MAY	CRLD	
		OMEPRAZOLE						
		CAPSULE, DELAYED REL PELLETS; ORAL						
		OMEPRAZOLE						
	AB	LEK SVCS	10MG	N75757 001	JAN 28, 2003	JAN	NEWA	
	AB		20MG	N75757 002	JAN 28, 2003	JAN	NEWA	
>A>	AB	MYLAN	10MG	N75876 001	MAY 29, 2003	MAY	NEWA	
>A>	AB		20MG	N75876 002	MAY 29, 2003	MAY	NEWA	
		ORPHENADRINE CITRATE						
		INJECTABLE; INJECTION						
		ORPHENADRINE CITRATE						
	AP	BEDFORD LABS	30MG/ML	N40463 001	MAR 04, 2003	MAR	NEWA	
		OXYBUTYNIN						
		FILM, EXTENDED RELEASE; TRANSDERMAL						
		OXYTROL						
		+ WATSON LABS (UTAH)	3.9MG/24HR	N21351 002	FEB 26, 2003	FEB	NEWA	
		OXYBUTYNIN CHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		DITROPAN XL						
>D>		+ ALZA	5MG	N20897 001	DEC 16, 1998	MAY	CRLD	
>A>			5MG	N20897 001	DEC 16, 1998	MAY	CRLD	
>D>		+	10MG	N20897 002	DEC 16, 1998	MAY	CRLD	
>A>			10MG	N20897 002	DEC 16, 1998	MAY	CRLD	

			OXYTOCIN					
			INJECTABLE; INJECTION					
			OXYTOCIN					
>A>			@ BAXTER HLTHCARE CORP	10USP UNITS/ML	N18243 001		MAY	CAHN
>D>			@ WYETH AYERST	10USP UNITS/ML	N18243 001		MAY	CAHN
			PANCURONIUM BROMIDE					
			INJECTABLE; INJECTION					
			PANCURONIUM BROMIDE					
>D>	AP		GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
>A>	AP	+		1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
>D>	AP			2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
>A>	AP	+		2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
			PAVULON					
>D>	AP	+	ORGANON	1MG/ML	N17015 002		MAY	DISC
>A>			@	1MG/ML	N17015 002		MAY	DISC
>D>	AP	+		2MG/ML	N17015 001		MAY	DISC
>A>			@	2MG/ML	N17015 001		MAY	DISC
			PANTOPRAZOLE SODIUM					
			INJECTABLE; IV (INFUSION)					
			PROTONIX IV					
		+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	CAHN
			TABLET, DELAYED RELEASE; ORAL					
			PROTONIX					
		+	WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
				EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
		+		EQ 40MG BASE	N20987 001	FEB 02, 2000	MAR	CAHN
			PAROMOMYCIN SULFATE					
			CAPSULE; ORAL					
			HUMATIN					
>A>	AA	+	KING PHARMS	EQ 250MG BASE	N62310 001		MAY	CAHN
>D>	AA	+	PARKEDALE	EQ 250MG BASE	N62310 001		MAY	CAHN
			PEGVISOMANT					
			INJECTABLE; SUBCUTANEOUS					
			SOMAVERT					
		+	PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
		+		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
		+		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA
			PERMETHRIN					
			CREAM; TOPICAL					
			PERMETHRIN					
	AB		CLAY PARK	5%	N76369 001	APR 21, 2003	APR	NEWA
			PERPHENAZINE					
			TABLET; ORAL					
			PERPHENAZINE					
	AB	+	IVAX PHARMS	16MG	N89457 001	SEP 10, 1987	FEB	CRLD

		PERPHENAZINE						
		TABLET; ORAL						
		TRILAFON						
		@ SCHERING	2MG	N10775 001			FEB	DISC
		@	4MG	N10775 002			FEB	DISC
		@	8MG	N10775 003			FEB	DISC
		@	16MG	N10775 004			FEB	DISC
		PHENTERMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		PHENTERMINE HCL						
	AA	ABLE	15MG	N40497 001	MAR 13, 2003		MAR	NEWA
>A>	AA	AMBI PHARMS	30MG	N40083 001	MAR 07, 1997		MAY	CAHN
	AA	AMIDE PHARM	15MG	N40460 001	JAN 14, 2003		JAN	NEWA
	AA		30MG	N40448 001	JAN 22, 2003		JAN	NEWA
>D>	AA	KING PHARMS	30MG	N40083 001	MAR 07, 1997		MAY	CAHN
		PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE						
		SYRUP; ORAL						
		PHENERGAN VC						
		@ WYETH AYERST	5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984		APR	DISC
		PROMETH VC PLAIN						
	AA +	ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984		APR	CRLD
		PHENYTOIN						
		SUSPENSION; ORAL						
		PHENYTOIN						
	AB	VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001		MAR	CAHN
		PHENYTOIN SODIUM						
		INJECTABLE; INJECTION						
		DILANTIN						
		@ PARKE DAVIS	50MG/ML	N10151 001			MAR	DISC
		PHENYTOIN						
	+	ELKINS SINN	50MG/ML	N84307 001			MAR	CRLD
		PHENYTOIN SODIUM						
		@ ABBOTT	50MG/ML	N89521 001	MAR 17, 1987		MAR	DISC
		@	50MG/ML	N89744 001	DEC 18, 1987		MAR	DISC
		PHENYTOIN SODIUM, EXTENDED						
		CAPSULE; ORAL						
		DILANTIN						
		PARKE DAVIS	30MG	N84349 001			FEB	CRLD
		PILOCARPINE HYDROCHLORIDE						
		TABLET; ORAL						
		SALAGEN						
		MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994		APR	CRLD
	+		7.5MG	N20237 002	APR 18, 2003		APR	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

+	WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002		MAR	CAHN
		EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
+		EQ 3GM BASE/VIAL	N50545 003		MAR	CAHN
		EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
+		EQ 4GM BASE/VIAL	N50545 004		MAR	CAHN
		EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
	@	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+	WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN

ZOSYN IN PLASTIC CONTAINER

+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

>D>	+	3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC
>A>		@	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

@	BAXTER HLTHCARE CORP	300MG/ML	N18799 001	DEC 13, 1982	MAR	CAHN

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>A>	AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN
>D>	AA	HALSEY	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN
	AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA
	AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA

PRELONE

>D>	AA +	MURO	15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN
>A>	AA +	TEVA	15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA		HI TECH PHARMA	EQ 5MG BASE/5ML	N75183 001	MAR 26, 2003	MAR	NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM
SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT		ALCON	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN

PREDNISONE
TABLET; ORAL
PREDNISONE

AB		VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

>A>	AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003	MAY	NEWA

PROMETHAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
PHENERGAN

		@	WYETH AYERST	50MG/ML	N08857 003		APR	DISC

PROMETHAZINE HCL

	AP	+	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
	AP	+		50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
	AP		PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003	MAR	NEWA

SUPPOSITORY; RECTAL
PHENERGAN

	AB	+	WYETH AYERST	50MG	N11689 001		FEB	CTEC
	AB		WYETH PHARMS INC	12.5MG	N10926 002		MAR	CAHN
	AB	+		25MG	N10926 001		MAR	CAHN
	AB	+		50MG	N11689 001		MAR	CAHN

PROMETHAZINE HCL

	AB		ABLE	12.5MG	N40504 001	APR 11, 2003	APR	NEWA
	AB			25MG	N40504 002	APR 11, 2003	APR	NEWA
	AB			50MG	N40449 001	FEB 27, 2003	FEB	NEWA
	AB		G AND W LABS	12.5MG	N40428 002	MAR 31, 2003	MAR	NEWA

TABLET; ORAL
PHENERGAN

			WYETH PHARMS INC	12.5MG	N07935 002		MAR	CAHN
	BP			25MG	N07935 003		MAR	CAHN
	BP	+		50MG	N07935 004		MAR	CAHN

PROPIOMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
LARGON

>A>		@	BAXTER HLTHCARE CORP	20MG/ML	N12382 002		MAY	CAHN
>D>		@	WYETH AYERST	20MG/ML	N12382 002		MAY	CAHN

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

			WYETH PHARMS INC	60MG	N18553 004	MAR 18, 1987	MAR	CAHN
	BX			80MG	N18553 002	APR 19, 1983	MAR	CTEC
	BX			120MG	N18553 003	APR 19, 1983	MAR	CTEC
		+		160MG	N18553 001	APR 19, 1983	MAR	CAHN

INNOPRAN XL

	BX		RELIANT PHARMS	80MG	N21438 001	MAR 12, 2003	MAR	NEWA
	BX			120MG	N21438 002	MAR 12, 2003	MAR	NEWA

INJECTABLE; INJECTION
INDERAL

>A>	AP	+	BAXTER HLTHCARE CORP	1MG/ML	N16419 001		MAY	CAHN
>D>	AP	+	WYETH AYERST	1MG/ML	N16419 001		MAY	CAHN

PROPRANOLOL HCL

	AP		SABEX 2002	1MG/ML	N76400 001	FEB 26, 2003	FEB	NEWA

TABLET; ORAL
INDERAL

	AB	+	WYETH PHARMS INC	10MG	N16418 001		MAR	CAHN
	AB			20MG	N16418 003		MAR	CAHN
	AB			40MG	N16418 002		MAR	CAHN
	AB			60MG	N16418 009	OCT 18, 1982	MAR	CAHN
	AB	+		80MG	N16418 004		MAR	CAHN
		@		90MG	N16418 010	OCT 18, 1982	MAR	CAHN

PYRIDOSTIGMINE BROMIDE
INJECTABLE; INJECTION
REGONOL

>D>	AP	+	ORGANON	5MG/ML	N17398 001		MAY	DISC
>A>		@		5MG/ML	N17398 001		MAY	DISC

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

	AB		IMPAX LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA
		@	US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA

QUETIAPINE FUMARATE
TABLET; ORAL
SEROQUEL

		+	ASTRAZENECA	EQ 25MG BASE	N20639 001	SEP 26, 1997	MAR	CRLD

QUINAPRIL HYDROCHLORIDE
TABLET; ORAL
ACCUPRIL

>D>			PFIZER PHARMS	EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG
>A>	AB			EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG
>D>				EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG
>A>	AB			EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG
>D>				EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG
>A>	AB			EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG
>D>		+		EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG
>A>	AB	+		EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG

QUINAPRIL HYDROCHLORIDE
TABLET; ORAL

>A>		QUINAPRIL HCL						
>A>	AB	TEVA	EQ 5MG BASE	N75504 001	MAY 30, 2003	MAY	NEWA
>A>	AB		EQ 10MG BASE	N75504 002	MAY 30, 2003	MAY	NEWA
>A>	AB		EQ 20MG BASE	N75504 003	MAY 30, 2003	MAY	NEWA
>A>	AB		EQ 40MG BASE	N75504 004	NOV 20, 1998	MAY	NEWA

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL

		QUINAGLUTE						
		@ BERLEX LABS	324MG	N16647 001		MAR	DISC
		QUINIDINE GLUCONATE						
>D>	BX +	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAY	CTEC
>A>	+		324MG	N89338 001	FEB 11, 1987	MAY	CTEC
	BX +		324MG	N89338 001	FEB 11, 1987	APR	CRLD
>D>	BX	WATSON LABS	324MG	N87810 001	SEP 29, 1982	MAY	DISC
>A>	@		324MG	N87810 001	SEP 29, 1982	MAY	DISC
	+		324MG	N87810 001	SEP 29, 1982	MAR	CRLD
	BX		324MG	N87810 001	SEP 29, 1982	APR	CRLD

QUINIDINE SULFATE
TABLET, EXTENDED RELEASE; ORAL

	QUINIDEX						
AB +	WYETH PHARMS INC	300MG	N12796 002		MAR	CAHN

RESERPINE; TRICHLORMETHIAZIDE
TABLET; ORAL

>D>		METATENSIN #2					
>D>		AVENTIS PHARMS	0.1MG;2MG	N12972 001		MAY	DISC
>A>	@		0.1MG;2MG	N12972 001		MAY	DISC
>D>		METATENSIN #4					
>D>	+	AVENTIS PHARMS	0.1MG;4MG	N12972 002		MAY	DISC
>A>	@		0.1MG;4MG	N12972 002		MAY	DISC

RILUZOLE
TABLET; ORAL

	RILUTEK						
AB +	AVENTIS	50MG	N20599 001	DEC 12, 1995	JAN	CFTG
	RILUZOLE						
AB	IMPAX LABS	50MG	N76173 001	JAN 29, 2003	JAN	NEWA

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL

	RIMANTADINE HCL						
AB	AMIDE PHARM	100MG	N76375 001	JAN 14, 2003	JAN	NEWA

RISPERIDONE
TABLET, ORALLY DISINTEGRATING; ORAL

	RISPERDAL						
	JOHNSON AND JOHNSON	0.5MG	N21444 001	APR 02, 2003	APR	NEWA

	+	1MG	N21444 002	APR 02, 2003	APR	NEWA
		2MG	N21444 003	APR 02, 2003	APR	NEWA
	ROSIGLITAZONE MALEATE					
	TABLET; ORAL					
	AVANDIA					
	SB PHARMCO	EQ 2MG BASE	N21071 002	MAY 25, 1999	APR	CAHN
		EQ 4MG BASE	N21071 003	MAY 25, 1999	APR	CAHN
	+	EQ 8MG BASE	N21071 004	MAY 25, 1999	APR	CAHN
	SACROSIDASE					
	SOLUTION; ORAL					
	SUCRAID					
>D>	+ ORPHAN MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998	MAY	CAHN
>A>	+ QOL MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998	MAY	CAHN
	SEVELAMER HYDROCHLORIDE					
	CAPSULE; ORAL					
	RENAGEL					
	+ GENZYME	403MG	N20926 001	OCT 30, 1998	APR	CAHN
	TABLET; ORAL					
	GENZYME	400MG	N21179 001	JUL 12, 2000	APR	CAHN
	+	800MG	N21179 002	JUL 12, 2000	APR	CAHN
	SIROLIMUS					
	SOLUTION; ORAL					
	RAPAMUNE					
	+ WYETH PHARMS INC	1MG/ML	N21083 001	SEP 15, 1999	MAR	CAHN
	TABLET; ORAL					
	WYETH PHARMS INC	1MG	N21110 001	AUG 25, 2000	MAR	CRLD
	+	2MG	N21110 002	AUG 22, 2002	MAR	NEWA
	SODIUM IODIDE, I-131					
	CAPSULE; ORAL					
	SODIUM IODIDE I 131					
	+ DRAXIMAGE	1-250mCi	N21305 002	JAN 24, 2003	JAN	NEWA
	+	1-500mCi	N21305 003	JAN 24, 2003	JAN	NEWA
	SOLUTION; ORAL					
	SODIUM IODIDE I 131, KIT					
	+ DRAXIMAGE	1-250mCi/0.25ML	N21305 002	JAN 24, 2003	FEB	CDFR
	+	1-500mCi/0.5ML	N21305 003	JAN 24, 2003	FEB	CDFR
	SOMATROPIN RECOMBINANT					
	INJECTABLE; INJECTION					
	BIO-TROPIN					
	@ BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995	MAR	DISC
	TEV-TROPIN					
BX	+ BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	FEB	CTNA
	SOTALOL HYDROCHLORIDE					
	TABLET; ORAL					
>D>	BETAPACE AF					
>D>	BERLEX LABS	40MG	N21151 006	APR 02, 2003	MAY	DISC

>A>		@	40MG	N21151 006	APR 02, 2003	MAY	DISC
			40MG	N21151 006	APR 02, 2003	APR	NEWA
>D>			60MG	N21151 007	APR 02, 2003	MAY	DISC
>A>		@	60MG	N21151 007	APR 02, 2003	MAY	DISC
			60MG	N21151 007	APR 02, 2003	APR	NEWA
>D>			100MG	N21151 005	MAR 14, 2003	MAY	DISC
>A>		@	100MG	N21151 005	MAR 14, 2003	MAY	DISC
			100MG	N21151 005	MAR 14, 2003	MAR	NEWA

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

AP	+	AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993	JAN	CFTG

STRONTIUM CHLORIDE SR-89

AP		BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003	JAN	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SEPTRA

>D>	AP	+	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001		MAY	DISC
>A>			@	80MG/ML;16MG/ML	N18452 001		MAY	DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

AB			ASTRAZENECA	EQ 10MG BASE	N17970 001		FEB	CTEC
AB	+			EQ 20MG BASE	N17970 002	MAR 21, 1994	FEB	CTEC

TAMOXIFEN CITRATE

AB			AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003	MAR	NEWA
AB				EQ 20MG BASE	N76398 002	MAR 31, 2003	MAR	NEWA
AB			ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N76179 002	FEB 20, 2003	FEB	NEWA
AB			BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N70929 002	FEB 20, 2003	FEB	NEWA
AB			IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N75740 002	FEB 20, 2003	FEB	NEWA
AB			MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA
AB			PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
AB				EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA
AB			ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA
AB			TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA
AB				EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
AB				EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
AB				EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN MDP KIT

AP	+	DRAXIMAGE	N/A	N18035 001		MAR	CRLD

>D>		TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT						
>D>		INJECTABLE; INJECTION						
>D>		PYROLITE						
>D>		CIS		N/A	N17684 001		MAY	DISC
>A>		@		N/A	N17684 001		MAY	DISC
		TESTOSTERONE						
		GEL; TOPICAL						
		ANDROGEL						
	BX	+ UNIMED PHARMS		1%	N21015 001	FEB 28, 2000	APR	CTEC
		TESTIM						
	BX	+ AUXILIUM A2		1%	N21454 001	OCT 31, 2002	APR	CTEC
		TETRACYCLINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		TETRACYCLINE HCL						
>A>	AB	AXIOM PHARM		250MG	N60736 001		MAY	CAHN
>A>	AB			500MG	N60736 002		MAY	CAHN
>D>	AB	HALSEY		250MG	N60736 001		MAY	CAHN
>D>	AB			500MG	N60736 002		MAY	CAHN
		THALIDOMIDE						
		CAPSULE; ORAL						
		THALOMID						
		CELGENE		100MG	N20785 002	JAN 17, 2003	JAN	NEWA
		+		200MG	N20785 003	JAN 17, 2003	JAN	NEWA
		THIOTHIXENE						
		CAPSULE; ORAL						
		NAVANE						
	AB	PFIZER		1MG	N16584 001		FEB	CAHN
	AB			2MG	N16584 002		FEB	CAHN
	AB	+		5MG	N16584 003		FEB	CAHN
	AB			10MG	N16584 004		FEB	CAHN
				20MG	N16584 005		FEB	CAHN
		THIOTHIXENE HYDROCHLORIDE						
		CONCENTRATE; ORAL						
	AA	+ PFIZER		EQ 5MG BASE/ML	N16758 001		FEB	CAHN
		INJECTABLE; INJECTION						
		@ PFIZER		EQ 2MG BASE/ML	N16904 001		FEB	CAHN
		+		EQ 10MG BASE/VIAL	N16904 002		FEB	CAHN
		TIZANIDINE HYDROCHLORIDE						
		TABLET; ORAL						
		TIZANIDINE HCL						
	AB	BARR		EQ 2MG BASE	N76371 001	APR 09, 2003	APR	NEWA
	AB			EQ 4MG BASE	N76371 002	APR 09, 2003	APR	NEWA
	AB	MYLAN		EQ 2MG BASE	N76354 001	MAR 28, 2003	MAR	NEWA
	AB			EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA

TORSEMIDE
TABLET; ORAL
TORSEMIDE

>A>	AB	PAR PHARM	5MG	N76226 001	MAY 27, 2003	MAY	NEWA
>A>	AB		10MG	N76226 002	MAY 27, 2003	MAY	NEWA
>A>	AB		20MG	N76226 003	MAY 27, 2003	MAY	NEWA
>A>	AB		100MG	N76226 004	MAY 27, 2003	MAY	NEWA
>A>	AB	PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003	MAY	NEWA
>A>	AB		10MG	N76346 002	MAY 30, 2003	MAY	NEWA
>A>	AB		20MG	N76346 003	MAY 30, 2003	MAY	NEWA

TRAMADOL HYDROCHLORIDE
TABLET; ORAL
TRAMADOL HCL

AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR	CAHN

TRIAMCINOLONE ACETONIDE
LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALTANA	0.025%	N40467 001	APR 21, 2003	APR	NEWA
AT		0.1%	N40467 002	APR 21, 2003	APR	NEWA

TRICHLORMETHIAZIDE
TABLET; ORAL

>D>		METAHYDRIN					
>D>	BP	AVENTIS PHARMS	2MG	N12594 001	JUN 16, 1988	MAY	DISC
>A>		@	2MG	N12594 001	JUN 16, 1988	MAY	DISC
>D>	BP		4MG	N12594 002	JUN 16, 1988	MAY	DISC
>A>		@	4MG	N12594 002	JUN 16, 1988	MAY	DISC

TRIMETHOPRIM
TABLET; ORAL
PROLOPRIM

>D>	AB	+	MONARCH PHARMS	200MG	N17943 003	JUL 14, 1982	MAY	DISC
>A>			@	200MG	N17943 003	JUL 14, 1982	MAY	DISC
			TRIMETHOPRIM					
>D>	AB		TEVA	200MG	N71259 001	JUN 18, 1987	MAY	CRLD
>A>		+		200MG	N71259 001	JUN 18, 1987	MAY	CRLD

UREA, C-13
FOR SOLUTION; ORAL

>D>			HELICOSOL					
>D>		+	METABOLIC SOLUTIONS	125MG/VIAL	N21092 001	DEC 17, 1999	MAY	DISC
>A>			@	125MG/VIAL	N21092 001	DEC 17, 1999	MAY	DISC
			PYLORI-CHEK BREATH TEST					
			@ DEVICES	100MG/VIAL	N20900 001	FEB 04, 1999	MAR	CAHN

VECURONIUM BROMIDE
INJECTABLE; INJECTION

>D>			NORCURON					
>D>	AP	+	ORGANON	10MG/VIAL	N18776 002	APR 30, 1984	MAY	DISC
>A>			@	10MG/VIAL	N18776 002	APR 30, 1984	MAY	DISC

		VECURONIUM BROMIDE						
		INJECTABLE; INJECTION						
		VECURONIUM BROMIDE						
>D>	AP	BEDFORD	10MG/VIAL	N75549 001	JUN 13, 2000	MAY	CRLD
>A>	AP +		10MG/VIAL	N75549 001	JUN 13, 2000	MAY	CRLD
		VENLAFAXINE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		EFFEXOR XR						
		WYETH PHARMS INC	EQ 37.5MG BASE	N20699 001	OCT 20, 1997	MAR	CAHN
			EQ 75MG BASE	N20699 002	OCT 20, 1997	MAR	CRLD
		@	EQ 100MG BASE	N20699 003	OCT 20, 1997	MAR	CAHN
		+	EQ 150MG BASE	N20699 004	OCT 20, 1997	MAR	CRLD
		TABLET; ORAL						
		EFFEXOR						
		@ WYETH PHARMS INC	EQ 12.5MG BASE	N20151 001	DEC 28, 1993	MAR	CAHN
			EQ 25MG BASE	N20151 002	DEC 28, 1993	MAR	CRLD
			EQ 37.5MG BASE	N20151 006	DEC 28, 1993	MAR	CAHN
			EQ 50MG BASE	N20151 003	DEC 28, 1993	MAR	CAHN
			EQ 75MG BASE	N20151 004	DEC 28, 1993	MAR	CAHN
		+	EQ 100MG BASE	N20151 005	DEC 28, 1993	MAR	CAHN
>D>		VIDARABINE						
>D>		OINTMENT; OPHTHALMIC						
>D>		VIRA-A						
>D>		+ PARKEDALE	3%	N50486 001		MAY	DISC
>A>		@	3%	N50486 001		MAY	DISC
		VINORELBINE TARTRATE						
		INJECTABLE; INJECTION						
		NAVELBINE						
	AP +	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N20388 001	DEC 23, 1994	FEB	CFTG
		VINORELBINE TARTRATE						
	AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N76028 001	FEB 03, 2003	FEB	NEWA
		ZOLEDRONIC ACID						
		INJECTABLE; IV (INFUSION)						
		ZOMETA						
		+ NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR	NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE
TABLET, CHEWABLE; ORAL
FOAMICON
NOVARTIS 80MG;20MG N72687 001 JUN 28, 1989 MAR CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE
@ CENT PHARMS 8MG;120MG N19428 001 AUG 02, 1988 MAR DISC

CIMETIDINE
TABLET; ORAL
CIMETIDINE
@ LEK PHARMS 100MG N75122 001 JUN 19, 1998 MAR CAHN
200MG N75122 002 JUN 19, 1998 MAR CAHN

EPINEPHRINE
AEROSOL, METERED; INHALATION
>D> BRONKAID MIST
>D> + STERLING 0.25MG/INH N16803 001 MAY DISC
>A> @ 0.25MG/INH N16803 001 MAY DISC

GUAIFENESIN
TABLET, EXTENDED RELEASE; ORAL
MUCINEX
ADAMS LABS 600MG N21282 001 JUL 12, 2002 JAN CRLD
+ 1.2GM N21282 002 DEC 18, 2002 JAN NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE
TABLET; ORAL
IMODIUM ADVANCED
+ MCNEIL CONS SPECLT 2MG;125MG N21140 001 NOV 30, 2000 JAN CRLD

LORATADINE
SYRUP; ORAL
CLARITIN
+ SCHERING 1MG/ML N20641 002 NOV 27, 2002 APR CRLD
1MG/ML N20641 002 NOV 27, 2002 MAR NEWA
TABLET; ORAL
+ SCHERING 10MG N19658 002 NOV 27, 2002 APR CRLD
10MG N19658 002 NOV 27, 2002 MAR NEWA
LORATADINE
GENEVA PHARMS 10MG N75209 001 JAN 21, 2003 JAN NEWA
TABLET, ORALLY DISINTEGRATING; ORAL
ALAVERT
WYETH CONS 10MG N21375 001 DEC 19, 2002 APR CRLD
CLARITIN REDITABS
+ SCHERING 10MG N20704 002 NOV 27, 2002 APR CRLD
10MG N20704 002 NOV 27, 2002 MAR NEWA
LORATADINE
WYETH CONS 10MG N75822 001 FEB 10, 2003 FEB NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D						
+ SCHERING	5MG;120MG	N19670 002	NOV 27, 2002	APR	CRLD
	5MG;120MG	N19670 002	NOV 27, 2002	MAR	NEWA
CLARITIN-D 24 HOUR						
+ SCHERING	10MG;240MG	N20470 002	NOV 27, 2002	APR	CRLD
	10MG;240MG	N20470 002	NOV 27, 2002	MAR	NEWA
LORATADINE AND PSEUDOEPHEDRINE HCL						
ANDRX PHARMS	10MG;240MG	N75706 001	FEB 21, 2003	FEB	NEWA
LORATADINE AND PSEUDOEPHEDRINE SULFATE						
IMPAX LABS	5MG;120MG	N76050 001	JAN 30, 2003	JAN	NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)					
MORTON GROVE	5%	N75438 001	FEB 27, 2003	FEB	NEWA

PERMETHRIN

LOTION; TOPICAL

NIX					
+ INSIGHT PHARMS	1%	N19918 001	MAY 02, 1990	MAR	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 5 MAY '03

NO MAY 2003 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
May 2003

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel 2310 boul Alfred-Nobel Saint-Laurent, Quebec Canada H4S 2A4
a-(3-aminophthalimido) Actimid	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Corporation Plant-Produced Human a-Glactosidase	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
alendronate Fosamax	DD: 3/31/2003 MA:	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
alteplase University Activase University Jefferson 1-109	DD: 1/27/2003 MA:	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD Johns Hopkins Johns Hopkins 600 N. Wolfe St., Baltimore MD 21287

Orphan Products Designations and Approvals List

May 2003

AMG 531	DD: 3/27/2003	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center
Drive	MA:		Thousand Oaks CA
91320-1799			
anti-CD23 IgG1, kappa monoclonal antibody	DD: 2/12/2003	Treatment of chronic lymphocytic leukemia	IDEC Pharmaceuticals, Inc.
	MA:		3030 Callan Road San Diego CA 92121
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)	DD: 5/21/2003	Treatment of pancreatic cancer	KS Biomedix Ltd Ground Floor, 1 Occam Court
	MA:		Surrey Research Park Guilford, Surrey, GU2
7HJ UK			
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	DD: 3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road
GTI-2040	MA: MA:		Toronto, Ontario M9W427 CANADA
arsenic trioxide	DD: 5/13/2003	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West
Trisenox	MA:		501 Elliott avenue West Suite 400 Seattle WA 98119
arsenic trioxide Trisenox	DD: 6/13/2003	Treatment of liver cancer	Cell Therapeutics, Inc. 501 Elliott Avenue West
	MA:		Suite 400 Seattle WA 98119
bifidobacterium longum infantis	DD: 1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health
Limited 35624	MA:		Guardwell, Kinsale County Cork, Ireland
bortezomib	DD: 1/15/2003	To treat multiple myeloma	Millennium
Pharmaceuticals, Inc. VELCADE	MA:		75 Sidney Street Cambridge MA 02139

Orphan Products Designations and Approvals List
May 2003

Capsaicin Park 4117	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
cinacalcet Drive 91320-1799	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Thousand Oaks CA
Defibrotide (CO)	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia ITALY
dextran 1 3B5	DD: 3/21/2003 MA:	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600 Toronto, Ontario M4P
DHA-paclitaxel Boulevard Taxoprexin Boulevard 19406	DD: 5/1/2003 MA:	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance 2200 Renaissance Suite 450 King of Prussia PA
diferuloylmethane LLC	DD: 6/13/2003 MA:	Treatment of cystic fibrosis	Seer Pharmarceuticals, P. O. Box 138 Southport CT 06890
diphenylcyclopenone	DD: 6/13/2003 MA: MA:	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr. 1900 Patterson Street Suite 104 Nashville TN 37203
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003 MA:	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue Seattle WA 98102

Orphan Products Designations and Approvals List
May 2003

Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway 1307	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Remicade Parkway 1307	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Remicade Parkway 1307	DD: 5/21/2003 MA:	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
INGN 201 Inc. ADVEXIN	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
iron(III)-hexacyanoferrate(II) Pharmzeutische KG Radiogardase-Cs / Antidotum Republic of	DD: 5/1/2003 MA: MA:	Treatment of patients with known or susupected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch- Fabrik GMBH & Co, Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
Mafosfamide (formerly Oncology)	DD: 1/21/2003 MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 franfurt/Main Germany
MaxAdFVIII Corporation 1113	DD: 3/3/2003 MA:	Treatment of Hemophilia A	GenStar Theraeutics 10865 Altman Row Suite 200 San Diego CA 92121-

Orphan Products Designations and Approvals List

May 2003

motexafin gadolinium Xcytrin 4521	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I APT070 Saffron Walden,	DD: 5/21/2003 MA: MA:	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Little Chesterford, Essex, CB10 1XK UK
polyinosinic-polycytidilic acid NW Poly-ICLC NW 3450	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp. 12085 Research Drive Suite 110 Alachua FL 32615
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of mutliple sclerosis patients who are both HLA-DR2 positive and glycoprotein residues 35-55 autoreactive to myelin oligodendrocyte	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila Italy

Orphan Products Designations and Approvals List
May 2003

repository corticotropin or Pharmaceuticals, Inc. adrenocorticotropic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-
resiniferatoxin	DD: 5/13/2003 MA: DASS/PPCS/NIDCR/NIH	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - 10 Convent Drive Bethesda MD 20892
Ribavirin USP Road REBETOL Road	DD: 4/4/2003 MA:	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill 2000 Galloping Hill Kenilworth NJ 07033
Sodium pyruvate	DD: 3/31/2003 MA:	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
suberoylanilide hydroxamic acid Road 6717	DD: 6/12/2003 MA:	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River Tarrytown NY 10591-
Tezacitabine 2916	DD: 1/27/2003 MA:	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-
Tretinoin ATRA-IV	DD: 4/11/2003 MA:	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2003 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE;ZIAGEN	5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
020978 001	ABACAVIR SULFATE;ZIAGEN	5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
020213 001	ACETYLCHOLINE CHLORIDE;MIOCHOL-E	6261546	APR 29, 2019	U-506		
020899 001	ALBUMIN HUMAN;OPTISON	5573751	APR 25, 2012			
		5529766	JUN 25, 2013	U-505		
		5558094	FEB 28, 2012	U-505		
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		I-309	SEP 29, 2003
		4621077	AUG 06, 2007	U-114	PED	MAR 29, 2004
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U-303		
		6090410*PED	JUN 02, 2013			
		6194004*PED	JUN 02, 2013			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U-114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	JUN 06, 2015	U-303		
		6090410*PED	JUN 02, 2013			
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U-114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U-303		
		6090410*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		6008207	JUN 06, 2015		PED	APR 20, 2004
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 16, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U-353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		5994329	JUL 17, 2018		PED	APR 20, 2004
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U-114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U-353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
021434 001	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 002	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 003	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 004	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
020221 002	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5954703	OCT 31, 2017	U-289		
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	OCT 21, 2018			
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	OCT 21, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	OCT 21, 2018			
	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	OCT 21, 2018			
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	OCT 21, 2018			
	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	OCT 21, 2018			
	040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	021549 001	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
			5538982	JUL 23, 2013			
			6048859	JUN 29, 2012			
			6096742	JUL 01, 2018			
			6235735	JUN 29, 2012			
	021549 002	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
			5538982	JUL 23, 2013			
			6048859	JUN 29, 2012			
			6096742	JUL 01, 2018			
			6235735	JUN 29, 2012			
	021436 001	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 002	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 003	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 004	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 005	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 006	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
>ADD>	021470 001	AZELAIC ACID;FINACEA	6534070	NOV 18, 2018			
>ADD>	021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U-509		
>ADD>	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U-510		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021602 001	BORTEZOMIB;VELCADE	5780454	OCT 28, 2014		NCE	MAY 13, 2008
>ADD>			6083903	OCT 28, 2014	U-515		
>ADD>			6297217	OCT 28, 2014	U-515		
>ADD>	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6562873	JUL 10, 2021			
>ADD>			6562873*PED	JAN 10, 2022			
>ADD>	076260 001	BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE				PC	SEP 16, 2003
	075766 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075766 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075823 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075823 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075836 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075836 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006		I-382	FEB 25, 2006
			4757128	AUG 01, 2006			
	020297 001	CARVEDILOL;COREG				I-388	MAR 27, 2006
	020297 002	CARVEDILOL;COREG				I-388	MAR 27, 2006
	020297 003	CARVEDILOL;COREG				I-388	MAR 27, 2006
	020297 004	CARVEDILOL;COREG				I-388	MAR 27, 2006
	021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U-295		
			4525358*PED	DEC 25, 2007	U-295		
			6469009	JUL 13, 2019	U-295		
			6469009*PED	JAN 13, 2020	U-295		
			6489329	APR 08, 2016			
			6489329*PED	OCT 08, 2016			
	021159 001	CICLOPIROX;LOPROX				NDF	FEB 28, 2006
	021473 001	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003		NDF	DEC 13, 2005
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6504030	JUN 10, 2019			
	019758 001	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
	019758 002	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U-323		
>ADD>	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U-323		
	017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL				D-78	FEB 03, 2006
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
			4863931	SEP 15, 2008		PED	JUN 21, 2007
			4804666	FEB 14, 2006	U-428		
			5595997	DEC 30, 2014	U-429		
			6100274	JUL 07, 2019			
			4659716*PED	OCT 21, 2004	U-427		
			4804666*PED	AUG 14, 2006	U-428		
			4863931*PED	MAR 15, 2009			
			5595997*PED	JUN 30, 2015	U-429		
			6100274*PED	JAN 07, 2020			
	021312 001	DESLORATADINE;CLARINEX				NCE	DEC 21, 2006
						PED	JUN 21, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
			5529791	JUN 25, 2013			
	020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
	020941 001	DOCOSANOL;ABREVA	4874794	APR 28, 2014			
>ADD>	020972 001	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019	U-248		
>ADD>	020972 002	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019	U-248		
>ADD>	020972 003	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019	U-248		
	021360 001	EFAVIRENZ;SUSTIVA	5663169	SEP 02, 2014			
	021481 001	ENFUVIRTIDE;FUZEON	5464933	JUN 07, 2013		NCE	MAR 13, 2008
			6133418	JUN 07, 2013			
	021437 001	EPLERENONE;INSPRA	6475491	JUN 07, 2015	U-248		
	021437 002	EPLERENONE;INSPRA	6534093	DEC 08, 2019	U-3		
	021437 003	EPLERENONE;INSPRA	6534093	DEC 08, 2019	U-3		
	019386 004	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6534093	DEC 08, 2019	U-3		
			6528540	JAN 12, 2021			
	019386 006	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
			6310094	JAN 12, 2021			
	019386 005	ESMOLOL HYDROCHLORIDE;BREVIBLOC DOUBLE STR	6528540	JAN 12, 2021			
			4593119	JUN 03, 2003			
	021367 001	ESTRADIOL ACETATE;FEMRING	6310094	JAN 12, 2021			
	021367 002	ESTRADIOL ACETATE;FEMRING	6528540	JAN 12, 2021			
>ADD>	020527 001	ESTROGENS, CONJUGATED;PREMPRO	4593119	JUN 03, 2003			
>ADD>	020527 003	ESTROGENS, CONJUGATED;PREMPRO	6310094	JAN 12, 2021			
>ADD>	020527 004	ESTROGENS, CONJUGATED;PREMPRO	6528540	JAN 12, 2021			
>ADD>			4593119	JUN 03, 2003			
>ADD>			6310094	JAN 12, 2021			
>ADD>	021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
>ADD>			5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
						D-79	MAR 12, 2006
						D-79	MAR 12, 2006
			RE36247	MAY 02, 2006		NP	MAR 12, 2006
			5547948	JAN 17, 2015		D-79	MAR 12, 2006
			5210081	FEB 26, 2012			
			5876746	JUN 07, 2015	U-514		
			5972377	JUN 07, 2015	U-514		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020747 001	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 002	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 003	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 004	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 005	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 006	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
>ADD>	019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
>ADD>			4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
>ADD>	019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
>ADD>			4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
>ADD>	019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
>ADD>			4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
>ADD>	019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
>ADD>			4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
>ADD>	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192	M-25	MAY 12, 2006
>ADD>			5855912	FEB 28, 2015		PED	NOV 12, 2006
			5738872	FEB 28, 2015			
			5932247	FEB 28, 2015			
			6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			
			6187791	MAY 11, 2012	U-138		
			6399632	MAY 11, 2012	U-468		
			5578610*PED	MAY 26, 2014	U-192		
			5738872*PED	AUG 28, 2015			
			5855912*PED	AUG 28, 2015			
			5932247*PED	AUG 28, 2015			
			6037353*PED	SEP 14, 2017	U-138		
			6113942*PED	AUG 28, 2015			
			6187791*PED	NOV 11, 2012	U-138		
			6399632*PED	NOV 11, 2012	U-468		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015		PED	AUG 25, 2003
>ADD>			5855912	FEB 28, 2015		M-25	MAY 12, 2006
>ADD>			6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
			6113942	FEB 28, 2015			
			6187791	MAY 11, 2012	U-138		
			6399632	MAY 11, 2012	U-468		
			5578610*PED	MAY 26, 2014	U-139		
			5855912*PED	AUG 28, 2015			
			5932247*PED	AUG 28, 2015			
			6037353*PED	SEP 14, 2017	U-138		
			6113942*PED	AUG 28, 2015			
			6187791*PED	NOV 11, 2012	U-138		
			6399632*PED	NOV 11, 2012	U-468		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015		PED	AUG 25, 2003
>ADD>			5855912	FEB 28, 2015		M-25	MAY 12, 2006
>ADD>			6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
			6113942	FEB 28, 2015			
			6187791	MAY 11, 2012	U-138		
			6399632	MAY 11, 2012	U-468		
			5578610*PED	MAY 26, 2014	U-139		
			5855912*PED	AUG 28, 2015			
			5932247*PED	AUG 28, 2015			
			6037353*PED	SEP 14, 2017	U-138		
			6113942*PED	AUG 28, 2015			
			6187791*PED	NOV 11, 2012	U-138		
			6399632*PED	NOV 11, 2012	U-468		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015		PED	AUG 25, 2003
>ADD>			5855912	FEB 28, 2015		M-25	MAY 12, 2006
>ADD>			6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
			6113942	FEB 28, 2015			
			6187791	MAY 11, 2012	U-138		
			6399632	MAY 11, 2012	U-468		
			5578610*PED	MAY 26, 2014	U-139		
			5855912*PED	AUG 28, 2015			
			5932247*PED	AUG 28, 2015			
			6037353*PED	SEP 14, 2017	U-138		
			6113942*PED	AUG 28, 2015			
			6187791*PED	NOV 11, 2012	U-138		
			6399632*PED	NOV 11, 2012	U-468		
>ADD>	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5578610	NOV 26, 2013		M-25	MAY 12, 2006
>ADD>			5855912	FEB 28, 2015		PED	NOV 12, 2006
			6037353	MAR 14, 2017	U-138		
			6039974	JUL 31, 2018			
			6113942	FEB 28, 2015			
			6187791	MAY 11, 2012	U-138		
			6399632	MAY 11, 2012	U-468		
			5578610*PED	MAY 26, 2014			
			5855912*PED	AUG 28, 2015			
			6037353*PED	SEP 14, 2017	U-138		
			6039974*PED	JAN 31, 2019			
			6113942*PED	AUG 28, 2015			
			6187791*PED	NOV 11, 2012	U-138		
			6399632*PED	NOV 11, 2012	U-468		
>ADD>	020180 001	FINASTERIDE;PROSCAR	6046183	MAR 20, 2011			
	020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
			4357324*PED	AUG 24, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
						PED	JUL 03, 2006
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
						PED	JUL 03, 2006
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
						PED	JUL 03, 2006
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
			5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
			4992474	FEB 12, 2008	U-211		
			5225445	FEB 12, 2008	U-211		
			5126375	FEB 12, 2008			
			5290815	MAR 01, 2011	U-386		
			4335121*PED	MAY 14, 2004			
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
			5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
			4992474	FEB 12, 2008	U-211		
			5225445	FEB 12, 2008	U-211		
			5126375	FEB 12, 2008			
			5290815	MAR 01, 2011	U-386		
			4335121*PED	MAY 14, 2004			
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
			5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
			4992474	FEB 12, 2008	U-211		
			5225445	FEB 12, 2008	U-211		
			5126375	FEB 12, 2008			
			5290815	MAR 01, 2011	U-386		
			4335121*PED	MAY 14, 2004			
	019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
			4335121*PED	MAY 14, 2004			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
			4335121*PED	MAY 14, 2004			
	020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		D-76	MAY 23, 2005
			4335121*PED	MAY 14, 2004		PED	NOV 23, 2005
>ADD>						M-24	MAY 01, 2006
>ADD>						PED	DEC 01, 2006
	020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
			4335121*PED	MAY 14, 2004			
	020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
			4335121*PED	MAY 14, 2004			
	020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
			4335121*PED	MAY 14, 2004			
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
			4335121*PED	MAY 14, 2004	U-409		
	020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
			5354772	OCT 11, 2011	U-413		
	020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
			5354772	OCT 11, 2011	U-413		
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
			5354772	OCT 11, 2011	U-109		
	020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019		I-342	SEP 25, 2004
	019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	021493 001	GATIFLOXACIN;ZYMAR				NDF	MAR 28, 2006
						NCE	DEC 17, 2004
>ADD>	021399 001	GEFITINIB;IRESSA				NCE	MAY 05, 2008
>ADD>	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6262071	SEP 21, 2019	U-513	NCE	APR 04, 2008
>ADD>			6331550	SEP 21, 2019	U-511		
>ADD>			6340689	SEP 14, 2019	U-512		
>ADD>			6455540	SEP 21, 2019	U-511		
	020329 001	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020329 002	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		
	020329 003	GLIPIZIDE;GLUCOTROL XL	4612008	SEP 16, 2003			
			5024843	SEP 05, 2009			
			5082668	SEP 16, 2003			
			5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		
			5591454	JAN 07, 2014	U-111		
	021282 002	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U-489		
>ADD>	021532 002	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U-500		
>ADD>	021532 003	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U-500		
>ADD>	021532 005	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U-500		
>ADD>	021455 001	IBANDRONATE SODIUM;BONIVA				NCE	MAY 16, 2008
	021321 001	ICODEXTRIN;EXTRANEAL	6248726	JUN 19, 2018	U-495		
			4761237	AUG 02, 2005	U-495		
			4886789	DEC 12, 2006	U-495		
			6077836	JUN 20, 2017	U-495		
>ADD>	021335 001	IMATINIB MESYLATE;GLEEVEC				I-392	MAY 20, 2006
>ADD>	021335 002	IMATINIB MESYLATE;GLEEVEC				I-392	MAY 20, 2006
	021588 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
>ADD>						I-376	DEC 20, 2005
>ADD>						ODE	FEB 01, 2009
>ADD>						ODE	MAY 10, 2008
>ADD>						I-391	MAY 20, 2006
	021588 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
>ADD>						I-376	DEC 20, 2005
>ADD>						ODE	FEB 01, 2009
>ADD>						ODE	MAY 10, 2008
>ADD>						I-391	MAY 20, 2006
>ADD>	021081 001	INSULIN GLARGINE;LANTUS				D-80	MAY 01, 2006
	021425 001	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U-498		
	021425 002	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U-498		
	020857 001	LAMIVUDINE;COMBIVIR	5047407*PED	MAY 17, 2010			
			5047407	NOV 17, 2009			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009			
			5047407*PED	MAY 17, 2010			
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009			
			5047407*PED	MAY 17, 2010			
	020241 001	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
	020241 002	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
	020241 003	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
	020241 004	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
	020241 005	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
	020241 006	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
	020764 004	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
	021488 001	LEUPROLIDE ACETATE;ELIGARD				NP	FEB 13, 2006
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
>ADD>	020634 001	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
>ADD>	020634 002	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
>ADD>	020634 003	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
>ADD>	020635 001	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
>ADD>	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
>ADD>	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
>ADD>	021199 001	LEVOFLOXACIN;QUIXIN	5503407	DEC 20, 2010			
	021301 001	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 002	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 003	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 004	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 005	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 006	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 007	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 008	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 009	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 010	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 011	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	021301 012	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	020612 001	LIDOCAINE;LIDODERM	5589180	MAR 17, 2009	U-485		
			5411738	MAY 02, 2012			
			5827529	OCT 27, 2015	U-486		
			5709869	MAR 17, 2009	U-485		
			5601838	MAY 02, 2012	U-488		
	021130 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021130 002	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021131 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021132 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021226 001	LOPINAVIR;KALETRA	6521651	NOV 01, 2017			
>ADD>	019658 002	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	020641 002	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>			6132758	JUN 01, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020704 002	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	019670 002	LORATADINE;CLARITIN-D	4659716	APR 21, 2004	U-142		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	020470 002	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>			5314697	OCT 23, 2012			
>ADD>			5314697*PED	APR 23, 2013			
	075209 001	LORATADINE;LORATADINE				PC	JUL 21, 2003
	075822 001	LORATADINE;LORATADINE				PC	AUG 09, 2003
	076050 001	LORATADINE;LORATADINE AND PSEUD				PC	JUL 30, 2003
	020386 001	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 002	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 003	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
>ADD>	021202 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018		NDF	OCT 13, 2003
>ADD>	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007			
	076119 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
	076119 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
>ADD>	076204 001	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
>ADD>	076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-385	FEB 28, 2006
	021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL	4990517	JUN 30, 2009	U-298	I-385	FEB 28, 2006
			5607942	MAR 04, 2014	U-298		
			5849752	DEC 05, 2016	U-298		
	021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	4990517	JUN 30, 2009		NDF	APR 15, 2006
			5607942	MAR 04, 2014		PED	OCT 15, 2006
			5849752	DEC 05, 2016			
			4990517*PED	DEC 30, 2009			
			5607942*PED	SEP 04, 2014			
			5849752*PED	JUN 05, 2017			
>ADD>	021204 001	NATEGLINIDE;STARLIX	6559188	SEP 17, 2019			
>ADD>	021204 002	NATEGLINIDE;STARLIX	6559188	SEP 17, 2019			
	021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
	021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
	020845 002	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013	U-297		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020845 003	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013	U-297		
	019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		ODE	MAY 22, 2003
			4551456	NOV 14, 2003	U-80	PED	NOV 22, 2003
			4382892*PED	MAR 02, 2004			
			4551456*PED	MAY 14, 2004	U-80		
	021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	5616599	APR 01, 2014	U-500		
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-500		
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-500		
	020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	4695578	JAN 25, 2005			
			4753789	JUN 24, 2006	U-44		
	020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA	6030643	MAY 16, 2017	U-497		
>ADD>	017577 001	OXYBUTYNIN CHLORIDE;DITROPAN				NPP	APR 15, 2006
>ADD>						PED	OCT 15, 2006
>ADD>	018211 001	OXYBUTYNIN CHLORIDE;DITROPAN				NPP	APR 15, 2006
>ADD>						PED	OCT 15, 2006
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
>ADD>						PED	OCT 15, 2006
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
>ADD>						PED	OCT 15, 2006
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
>ADD>						PED	OCT 15, 2006
>ADD>	021351 002	OXYBUTYNIN;OXYTROL				NDF	FEB 26, 2006
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6548084	JUL 19, 2016			
>ADD>			6548084*PED	JAN 19, 2017			
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6548084	JUL 19, 2016			
>ADD>			6548084*PED	JAN 19, 2017			
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	6548084	JUL 19, 2016			
>ADD>			6548084*PED	JAN 19, 2017			
	021106 001	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	021106 002	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	021106 003	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	020629 001	PENCICLOVIR SODIUM;DENAVIR	6469015	OCT 22, 2019	U-501		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	076061 001	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	076061 002	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	076061 003	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	021438 001	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
	021438 002	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
>ADD>	019901 001	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U-71		
>ADD>	019901 002	RAMIPRIL;ALTACE	5403856	APR 01, 2012	U-71		
>ADD>	019901 003	RAMIPRIL;ALTACE	5403856	APR 01, 2012	U-71		
>ADD>	019901 004	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U-71		
>ADD>	020903 001	RIBAVIRIN;REBETOL	6524570	NOV 01, 2016	U-499	M-26	MAR 06, 2005
			6524570*PED	MAY 01, 2017	U-499		
>ADD>	020903 002	RIBAVIRIN;REBETOL				M-26	MAR 06, 2005
	021444 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	021444 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	021444 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U-503		
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
	019766 001	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
	019766 002	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
	019766 003	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
	019766 004	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
	019766 005	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
	021083 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
	021110 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
	021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U-291	I-386	APR 11, 2006
			5308847	MAY 03, 2011	U-292		
			5403833	APR 04, 2012	U-293		
			5989591	MAR 11, 2018			
>ADD>	020231 001	SODIUM FLUORIDE;COLGATE TOTAL	5288480	JUL 16, 2008			
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				ODE	OCT 31, 2004
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
			5849700	DEC 15, 2015	U-340		
			5849704	DEC 15, 2015			
	021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
			5849700	DEC 15, 2015	U-340		
			5849704	DEC 15, 2015			
	021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
			5849700	DEC 15, 2015	U-340		
			5849704	DEC 15, 2015			
	021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
>ADD>	021151 006	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
>ADD>						PED	AUG 22, 2003
>ADD>	021151 007	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
>ADD>						PED	AUG 22, 2003
	020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
			4978655*PED	DEC 24, 2008			
>ADD>	021453 001	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248	NDF	DEC 21, 2003
>ADD>			4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2004
>ADD>	021453 002	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2003
>ADD>			4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2004
>ADD>	021453 003	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2003
>ADD>			4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2004
>ADD>	021453 004	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2003
>ADD>			4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2004
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	6121314	MAY 18, 2012	U-502		
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	6121314	MAY 18, 2012	U-504		
	020489 001	TESTOSTERONE;ANDRODERM	4863970	NOV 14, 2006			
			4983395	NOV 12, 2007			
			5152997	DEC 11, 2010	U-490		
			5164190	DEC 11, 2010			
			4849224	NOV 12, 2007			
			4855294	SEP 06, 2008			
	020489 002	TESTOSTERONE;ANDRODERM	4849224	NOV 12, 2007			
			4855294	SEP 06, 2008			
			4863970	NOV 14, 2006			
			4983395	NOV 12, 2007			
			5152997	DEC 11, 2010	U-490		
			5164190	DEC 11, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021454 001	TESTOSTERONE;TESTIM				NP	OCT 31, 2005
>ADD>	020785 001	THALIDOMIDE;THALOMID	6561977	OCT 23, 2020			
>ADD>			6561976	AUG 28, 2018			
>ADD>	020785 002	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371	ODE	JUL 16, 2005
>ADD>			6315720	OCT 23, 2020	U-442		
>ADD>			6561977	OCT 23, 2020			
>ADD>			6561976	AUG 28, 2018			
>ADD>	020785 003	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371	ODE	JUL 16, 2005
>ADD>			6315720	OCT 23, 2020	U-442		
>ADD>			6561977	OCT 23, 2020			
>ADD>			6561976	AUG 28, 2018			
	020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
>ADD>	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
	021257 001	TRAVOPROST;TRAVATAN				M-23	FEB 13, 2006
	021108 001	TRETINOIN;RENOVA	6531141	MAR 07, 2020			
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-381	SEP 09, 2005
						I-389	APR 01, 2006
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-381	SEP 09, 2005
						I-389	APR 01, 2006
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
			6146662	AUG 14, 2007	U-366		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
			6146662	AUG 14, 2007	U-366		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

EXCLUSIVITY DOSING SCHEDULE

D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS

EXCLUSIVITY INDICATION

I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	TX OF PED PTS W/PH+ CHRONIC PHASE CML WHOSE DISEASE RECUR AFTER STEM CELL TRANSPLANT OR WHO ARE RESIST TO INTERFERON ALPHA. NO CONTROLLED TRIALS DEMONSTRATE CLIN BENEFIT, SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASING SURVIVAL
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS

EXCLUSIVITY MISCELLANEOUS

M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01

PATENT USE

U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY

United States Government
INFORMATION
PUBLICATIONS ★ PERIODICALS ★ ELECTRONIC PRODUCTS

Approved Drug Products, ADP
SUBSCRIPTION ORDER FORM

Order Processing
Code: 8392

Easy Secure Internet:
bookstore.gpo.gov

Toll Free: 866 512–1800
Phone: 202 512–1800
Fax: 202 512–2250

Mail: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250–7954

❑ **YES,** enter my subscription(s) as follows:

_____subscription(s) of the ***Approved Drug products with Therapeutic Equivalence Evaluations, ADP,*** and the monthly Cumulative Supplements, for $108.00 per year. The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

Personal name (Please type or print)

Company name

Street address City, State, Zip code

Daytime phone including area code

Purchase Order Number

Check method of payment:

❑ Check payable to Superintendent of Documents

❑ SOD Deposit Account ☐☐☐☐☐☐☐ — ☐

❑ VISA ❑ MasterCard ❑ Discover/NOVUS ❑ American Express

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

☐☐☐☐ (expiration date)

Thank you for your order!

Authorizing signature

02/03